Celgene (CELG) 10-Q 29 Oct 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 22, 2013
Document and Entity Information
Entity Registrant Name	CELGENE CORP /DE/
Entity Central Index Key	816284
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	30-Sep-13
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		412,069,519

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue:
Net product sales	$1,644	$1,388	$4,637.40	$3,970.10
Collaborative agreements and other revenue	2.2	2.3	12.4	8.2
Royalty revenue	28.2	28.9	88.2	81
Total revenue	1,674.40	1,419.20	4,738	4,059.30
Expenses:
Cost of goods sold (excluding amortization of acquired intangible assets)	86.2	74.6	247.6	219
Research and development	584.5	441.5	1,495	1,250.70
Selling, general and administrative	448.7	354.6	1,235.80	1,003.40
Amortization of acquired intangible assets	65.7	46.2	197.1	132.1
Acquisition related charges and restructuring, net	33.7	0.7	79.4	28.9
Total costs and expenses	1,218.80	917.6	3,254.90	2,634.10
Operating income	455.6	501.6	1,483.10	1,425.20
Other income and (expense):
Interest and investment income, net	5.3	2.8	14.6	9.6
Interest (expense)	-24	-17.9	-61.5	-40.7
Other income (expense), net	5.1	-10	12	-2.9
Income before income taxes	442	476.5	1,448.20	1,391.20
Income tax provision	69.5	52.3	212.7	198.1
Net income	$372.50	$424.20	$1,235.50	$1,193.10
Net income per common share:
Basic (in dollars per share)	$0.90	$0.99	$2.98	$2.75
Diluted (in dollars per share)	$0.87	$0.97	$2.87	$2.69
Weighted average shares:
Basic (in shares)	412.3	427.2	414.7	434.1
Diluted (in shares)	428.8	436.3	430.5	443.4

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Statement of Other Comprehensive Income [Abstract]
Net income	$372.50	$424.20	$1,235.50	$1,193.10
Other comprehensive income (loss):
Foreign currency translation adjustments	17.9	4.7	22	6.8
Change in functional currency of a foreign subsidiary	0	0	0	13.1
Net unrealized gains (losses) related to cash flow hedges:
Unrealized holding gains (losses), net of tax expense (benefit) of ($0.2) and ($1.3) for the three-months ended September 30, 2013 and 2012, respectively, and $0 and ($13.1) for the nine-months ended September 30, 2013 and 2012, respectively.	-89.6	-26.8	-3.2	21.1
Reclassification adjustment for (gains) losses included in net income, net of tax (expense) benefit of $0.3 and $0.6 for the three-months ended September 30, 2013 and 2012, respectively, and $6.5 and ($2.4) for the nine-months ended September 30, 2013 and 2012, respectively.	-11.4	-24.9	-11.6	-59.9
Net unrealized gains (losses) on marketable securities available for sale:
Unrealized holding gains (losses), net of tax expense (benefit) of $58.5 and $0 for the three-months ended September 30, 2013 and 2012, respectively, and $78.4 and ($0.1) for the nine-months ended September 30, 2013 and 2012, respectively.	104.6	1.7	137.6	3.3
Reclassification adjustment for (gains) losses included in net income, net of tax (expense) benefit of $0.8 and $0 for the three-months ended September 30, 2013 and 2012, respectively, and $1.8 and $0 for the nine-months ended September 30, 2013 and 2012, respectively.	2.2	0.4	4.4	0.1
Total other comprehensive income (loss)	23.7	-44.9	149.2	-15.5
Comprehensive income	$396.20	$379.30	$1,384.70	$1,177.60

CONSOLIDATED_STATEMENTS_OF_COM1

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net unrealized gains (losses) related to cash flow hedges:
Unrealized holding gains (losses), tax expense (benefit)	($0.20)	($1.30)	$0	($13.10)
Reclassification adjustment for (gains) losses included in net income, tax (expense) benefit	0.3	0.6	6.5	-2.4
Net unrealized gains (losses) on marketable securities available for sale:
Unrealized holding gains (losses), tax expense (benefit)	58.5	0	78.4	-0.1
Reclassification adjustment for (gains) losses included in net income, tax (expense) benefit	$0.80	$0	$1.80	$0

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Current assets:
Cash and cash equivalents	$2,423	$2,090.40
Marketable securities available for sale	3,424.30	1,809.90
Accounts receivable, net of allowances of $44.0 and $33.0 at September 30, 2013 and December 31, 2012, respectively	1,093.30	960.5
Inventory	313.3	259.5
Deferred income taxes	5.5	93.2
Other current assets	387.8	320.2
Total current assets	7,647.20	5,533.70
Property, plant and equipment, net	592.3	578.4
Intangible assets, net	2,908.20	3,100.40
Goodwill	2,042.10	2,042.80
Other assets	439.3	479
Total assets	13,629.10	11,734.30
Current liabilities:
Short-term borrowings	405.9	308.5
Accounts payable	139.6	145.6
Accrued expenses	870.1	775.7
Income taxes payable	9.9	11.8
Current portion of deferred revenue	44.8	17.3
Other current liabilities	471	431.3
Total current liabilities	1,941.30	1,690.20
Deferred revenue, net of current portion	20.8	16.2
Income taxes payable	209.6	188.2
Deferred income taxes	857	1,018.40
Other non-current liabilities	477.4	355.5
Long-term debt, net of discount	4,228.30	2,771.30
Total liabilities	7,734.40	6,039.80
Commitments and Contingencies (Note 15)
Stockholders’ Equity:
Preferred stock, $.01 par value per share, 5.0 million shares authorized; none outstanding at September 30, 2013 and December 31, 2012, respectively	0	0
Common stock, $.01 par value per share, 575.0 million shares authorized; issued 509.5 million and 498.4 million shares at September 30, 2013 and December 31, 2012, respectively	5.1	5
Common stock in treasury, at cost; 96.9 million and 78.7 million shares at September 30, 2013 and December 31, 2012, respectively	-6,930.10	-4,823.20
Additional paid-in capital	8,462.10	7,539.80
Retained earnings	4,258.10	3,022.60
Accumulated other comprehensive income (loss)	99.5	-49.7
Total stockholders’ equity	5,894.70	5,694.50
Total liabilities and stockholders’ equity	$13,629.10	$11,734.30

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, allowances (in dollars)	$44	$33
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	575,000,000	575,000,000
Common stock, shares issued	509,500,000	498,400,000
Common stock, treasury	96,900,000	78,700,000

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net income	$1,235.50	$1,193.10
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	71.8	59.9
Amortization	205	133
Provision for accounts receivable allowances	8.3	14.6
Deferred income taxes	-161.5	143.6
Impairment charges	18.8	64.9
Change in value of contingent consideration	79.5	26.3
Share-based compensation expense	227.4	171
Share-based employee benefit plan expense	25.2	15.1
Reclassification adjustment for cash flow hedges included in net income	-5.1	-62.4
Unrealized change in value of derivative instruments	10.8	47.9
Realized losses on marketable securities available for sale	6	0.2
Other, net	0.1	1.3
Change in current assets and liabilities, excluding the effect of acquisitions:
Accounts receivable	-138.7	-34.6
Inventory	-62.6	-46.3
Other operating assets	-49.7	182.8
Assets held for sale, net	0	-1.2
Accounts payable and other operating liabilities	150.7	99.2
Income tax payable	22	-469.1
Deferred revenue	31.7	-0.3
Net cash provided by operating activities	1,675.20	1,539
Cash flows from investing activities:
Proceeds from sales of marketable securities available for sale	1,936.20	1,188.70
Purchases of marketable securities available for sale	-3,237.30	-1,517.50
Payments for acquisition of business, net of cash acquired	0	-352.2
(Purchases) sales of intellectual property and other assets	-19.4	15.8
Capital expenditures	-93.1	-81.9
Purchases of investment securities	-27.9	-30
Other investing activities	-1.9	-1
Net cash used in investing activities	-1,443.40	-778.1
Cash flows from financing activities:
Payment for treasury shares	-2,068	-1,481.20
Proceeds from short-term borrowing	3,761	3,874.40
Principal repayments on short-term borrowing	-3,665.90	-4,075.40
Proceeds from the issuance of long-term debt	1,479.60	1,486.70
Net proceeds from exercise of common stock options and warrants	458	321
Excess tax benefit from share-based compensation arrangements	139	19.9
Net cash provided by financing activities	103.7	145.4
Effect of currency rate changes on cash and cash equivalents	-2.9	-50.3
Net increase in cash and cash equivalents	332.6	856
Cash and cash equivalents at beginning of period	2,090.40	1,859.50
Cash and cash equivalents at end of period	2,423	2,715.50
Supplemental schedule of non-cash investing and financing activity:
Change in net unrealized (gain) loss on marketable securities available for sale	-216.2	-3.2
Matured shares tendered in connection with stock option exercises	-0.1	-0.2
Supplemental disclosure of cash flow information:
Interest paid	67.4	25
Income taxes paid	$226.20	$369.60

Nature_of_Business_and_Basis_o

Nature of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	Nature of Business and Basis of Presentation
	Celgene Corporation, together with its subsidiaries (collectively “we,” “our,”  “us,” “Celgene” or the “Company”) is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.  We are dedicated to innovative research and development designed to bring new therapies to market and are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.
	Our primary commercial stage products include REVLIMID®, VIDAZA®, ABRAXANE®, POMALYST®/IMNOVID®, THALOMID® (inclusive of Thalidomide Celgene®) and ISTODAX®.
	During the nine-months ended September 30, 2013, we received the following approvals in major markets for new products or additional approvals for existing products:
	•	REVLIMID® was approved for an additional indication by the U.S. Food and Drug Administration (FDA) in June 2013 for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which must include bortezomib.
	•	REVLIMID® was also approved by the European Commission (EC) in June 2013 for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndrome (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
	•	ABRAXANE® was approved for an additional indication by the FDA in September 2013 as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
	•	POMALYST® received its first approval from the FDA in February 2013 for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
	•	POMALYST® (sold in the European Union (EU) under the trade name IMNOVID®) was approved by the EC in August 2013, in combination with dexamethasone, for adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including both lenalidomide and bortezomib and have demonstrated disease progression on the last therapy.
	Additional sources of revenue include royalties from Novartis on their sales of FOCALIN XR® and the entire RITALIN® family of drugs, the sale of services through our Celgene Cellular Therapeutics subsidiary and other licensing agreements.
	The consolidated financial statements include the accounts of Celgene Corporation and its subsidiaries. Investments in limited partnerships and interests where we have an equity interest of 50% or less and do not otherwise have a controlling financial interest are accounted for by either the equity or cost method.  Certain prior year amounts have been reclassified to conform to the current year’s presentation.
	The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect reported amounts and disclosures.  Actual results could differ from those estimates.  We are subject to certain risks and uncertainties related to, among other things, product development, regulatory approval, market acceptance, scope of patent and proprietary rights, competition, outcome of civil and governmental proceedings, European credit risk, technological change and product liability.
	Interim results may not be indicative of the results that may be expected for the full year.  In the opinion of management, these unaudited consolidated financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim unaudited consolidated financial statements.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Our significant accounting policies are described in Note 1 of Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2012 (2012 Annual Report on Form 10-K). The following additional significant accounting policies also apply:
	Investments in Other Entities: Investments in equity securities of companies that become publicly traded are accounted for as available-for-sale marketable securities prospectively from the date of such companies' initial public offering.
	New Accounting Pronouncements: In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update “Comprehensive Income (Topic 220):  Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” (ASU 2013-2).  ASU 2013-2 requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under U.S. generally accepted accounting principles (GAAP) to be reclassified in its entirety to net income.  The amendments require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component.  An entity shall provide this information together, in one location, either on the face of the statement where net income is presented or as a separate disclosure in the notes to the financial statements.  The amendments are effective prospectively for reporting periods beginning after December 15, 2012.  The adoption of ASU 2013-2 did not have a material impact on our financial position or results of operations.
	In July 2013, the FASB issued Accounting Standards Update "Derivatives and Hedging (Topic 815): Inclusion of the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a Benchmark Interest Rate for Hedge Accounting Purposes" (ASU 2013-10). ASU 2013-10 permits the use of the Fed Funds Effective Swap Rate (also referred to as the Overnight Index Swap Rate), in addition to the U.S. government rate (UST) and London Interbank Offered Rate (LIBOR), as a U.S. benchmark interest rate for hedge accounting purposes. This update is effective prospectively for qualifying new or re-designated hedging relationships entered into on or after July 17, 2013. The adoption of ASU 2013-10 did not have a material impact on our financial position or results of operations.
	In July 2013, the FASB issued Accounting Standards Update "Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists" (ASU 2013-11). ASU 2013-11 requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss (NOL) carryforward, or similar tax loss or tax credit carryforward, rather than as a liability when (1) the uncertain tax position would reduce the NOL or other carryforward under the tax law of the applicable jurisdiction and (2) the entity intends to use the deferred tax asset for that purpose. ASU 2013-11 is effective prospectively for fiscal years and interim periods within those years, beginning after December 15, 2013 for public entities. Early adoption and retrospective application are permitted. We do not expect the adoption of ASU 2013-11 to have a material impact on our financial position or results of operations.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]
Acquisitions	Acquisitions
	Avila Acquisition
	On March 7, 2012 (Acquisition Date) we acquired all of the outstanding common stock of Avila Therapeutics, Inc., which was subsequently renamed Celgene Avilomics Research (Avila).  The acquisition resulted in Avila becoming our wholly-owned subsidiary.  The results of operations for Avila are included in our consolidated financial statements from the Acquisition Date and the assets and liabilities of Avila have been recorded at their respective fair values on the Acquisition Date and consolidated with our other assets and liabilities.
	We paid $352.2 million in cash, net of cash acquired and we may make additional payments based on achievement of developmental and regulatory milestones.  Our potential contingent milestone payments are classified as liabilities, which were measured at fair value as of the Acquisition Date.  The range of potential milestone payments is from no payment if none of the milestones are achieved to an estimated maximum of $595.0 million if all milestones are achieved.  The potential milestones consist of the initiation of phase II and phase III studies, investigational new drug (IND) filings and other regulatory events related to certain potential products in various stages of development.
	Contingent Value Rights
	In connection with the acquisition of Abraxis BioScience, Inc. (Abraxis) on October 15, 2010, we issued Contingent Value Rights (CVRs). Each holder of a CVR is entitled to receive a pro rata portion, based on the number of CVRs then outstanding, of contingent cash payments.
	In September 2013, the FDA approved ABRAXANE® for use in the treatment of pancreatic cancer, permitting us to market ABRAXANE® with a label that includes an overall survival claim. This approval resulted in the achievement of milestone #2 and the subsequent payment of the $300 million milestone on October 4, 2013 in accordance with the CVR agreement. The fair value of our total liability related to the CVRs was $347.9 million on September 30, 2013 and $277.4 million on December 31, 2012. For more information, see Note 2 of Notes to Consolidated Financial Statements included in our 2012 Annual Report on Form 10-K.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share
		Three-Month Periods Ended September 30,				Nine-Month Periods Ended September 30,
	(Amounts in millions, except per share)	2013		2012		2013		2012
	Net income	$	372.5	$	424.2	$	1,235.50	$	1,193.10
	Weighted-average shares:
	Basic	412.3		427.2		414.7		434.1
	Effect of dilutive securities:
	Options, restricted stock units, warrants and other incentives	16.5		9.1		15.8		9.3
	Diluted	428.8		436.3		430.5		443.4
	Net income per share:
	Basic	$	0.9	$	0.99	$	2.98	$	2.75
	Diluted	$	0.87	$	0.97	$	2.87	$	2.69
	The total number of potential shares of common stock excluded from the diluted earnings per share computation because their inclusion would have been anti-dilutive was 4.1 million and 11.6 million shares for the three-month periods ended September 30, 2013 and 2012, respectively. The total number of potential shares of common stock excluded for the nine-month periods ended September 30, 2013 and 2012 was 5.1 million and 11.5 million, respectively.
	During the period of April 2009 through September 2013, our Board of Directors has approved repurchases of up to an aggregate of $9.500 billion of our common stock, including the June 2013 authorization to repurchase an additional $3.000 billion of our common stock.
	As part of the Board authorized share repurchase program, in February 2013 we entered into an Accelerated Share Repurchase (ASR) agreement with an investment bank to repurchase an aggregate of $600.0 million of our common stock. The total number of shares repurchased under the ASR agreement was 5.2 million shares at a weighted average price of $114.30 per share.
	We have repurchased 1.5 million and 17.8 million shares of common stock under the program from all sources, including the ASR, during the three- and nine-month periods ended September 30, 2013, respectively. As of September 30, 2013, we had a remaining open-ended repurchase authorization of $2.790 billion.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss)
	The components of other comprehensive income (loss) consist of changes in pension liability, changes in net unrealized gains (losses) on marketable securities classified as available-for-sale, net unrealized gains (losses) related to cash flow hedges and changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency.
	The accumulated balances related to each component of other comprehensive income (loss), net of tax, are summarized as follows:
		Pension				Net Unrealized			Net Unrealized				Foreign				Total
		Liability				Gains (Losses) From			Gains (Losses)				Currency				Accumulated
						Marketable Securities			From Hedges				Translation				Other
													Adjustment				Comprehensive
																	Income (Loss)
	Balance December 31, 2012	$	(10.1	)		$	4.2		$	(16.1	)		$	(27.7	)		$	(49.7	)
	Other comprehensive income (loss) before reclassifications	—				137.6			(3.2		)		22				156.4
	Amounts reclassified from accumulated other comprehensive income	—				4.4			(11.6		)		—				(7.2		)
	Net current-period other comprehensive income (loss)	—				142			(14.8		)		22				149.2
	Balance September 30, 2013	$	(10.1	)		$	146.2		$	(30.9	)		$	(5.7	)		$	99.5
	Balance December 31, 2011	$	(5.4	)		$	1.8		$	8.7			$	(67.4	)		$	(62.3	)
	Other comprehensive income before reclassifications	—				3.3			21.1				19.9				44.3
	Amounts reclassified from accumulated other comprehensive income	—				0.1			(59.9		)		—				(59.8		)
	Net current-period other comprehensive income (loss)	—				3.4			(38.8		)		19.9				(15.5		)
	Balance September 30, 2012	$	(5.4	)		$	5.2		$	(30.1	)		$	(47.5	)		$	(77.8	)
					Gains (Losses) Reclassified Out of Accumulated
					Other Comprehensive Income
	Accumulated Other Comprehensive		Affected Line Item in the Consolidated Statements of		Three-Month Periods Ended September 30,							Nine-Month Periods Ended September 30,
	Income Components		Income		2013			2012				2013				2012
	Gains (losses) from cash-flow hedges:
	Foreign exchange contracts		Net product sales		$	12		$	24.8			$	7.6			$	62.8
	Treasury rate lock agreements		Interest (expense)		(0.9		)	(0.5		)		(2.5		)		(0.5		)
			Income tax benefit (expense)		0.3			0.6				6.5				(2.4		)
	Gains (losses) from available-for-sale marketable securities:
	Realized income (loss) on sales of marketable securities		Interest and investment income, net		(3.0		)	(0.4		)		(6.2		)		(0.1		)
			Income tax benefit		0.8			—				1.8				—
	Total reclassification, net of tax				$	9.2		$	24.5			$	7.2			$	59.8

Financial_Instruments_and_Fair

Financial Instruments and Fair Value Measurement	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurement	Financial Instruments and Fair Value Measurement
	The table below presents information about assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2013 and the valuation techniques we utilized to determine such fair value.  Fair values determined based on Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities.  Our Level 1 assets consist of marketable equity securities.  Fair values determined based on Level 2 inputs utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active.  Our Level 2 assets consist primarily of U.S. Treasury securities, U.S. government-sponsored agency securities, U.S. government-sponsored agency mortgage-backed securities, non-U.S. government, agency and Supranational securities, global corporate debt securities, asset backed securities, foreign currency forward contracts, purchased foreign currency options and interest rate swap contracts.  Fair values determined based on Level 3 inputs utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity.  We do not have any Level 3 assets.  Our Level 1 liability relates to our publicly traded CVRs. See Note 2 of Notes to Consolidated Financial Statements included in our 2012 Annual Report on Form 10-K for a description of the CVRs.  Our Level 2 liabilities relate to interest rate swap contracts, forward starting interest rate swap contracts and written foreign currency options.  Our Level 3 liabilities consist of contingent consideration related to undeveloped product rights resulting from the acquisition of Gloucester Pharmaceuticals, Inc. (Gloucester) and contingent consideration related to the undeveloped product rights and the technology platform acquired from the Avila acquisition.  The maximum potential payments related to the contingent consideration from the acquisitions of Gloucester and Avila are estimated to be $120.0 million and $595.0 million, respectively.
		Balance at			Quoted Price in			Significant			Significant
		September 30, 2013			Active Markets for			Other Observable			Unobservable
					Identical Assets			Inputs			Inputs
					(Level 1)			(Level 2)			(Level 3)
	Assets:
	Available-for-sale securities	$	3,424.30		$	422.3		$	3,002.00		$	—
	Cash equivalents	52			—			52			—
	Total assets	$	3,476.30		$	422.3		$	3,054.00		$	—
	Liabilities:
	Forward currency contracts	$	(8.9	)	$	—		$	(8.9	)	$	—
	Contingent value rights	(347.9		)	(347.9		)	—			—
	Written currency options	(0.3		)	—			(0.3		)	—
	Interest rate swaps	(31.5		)	—			(31.5		)	—
	Other acquisition related contingent consideration	(207.0		)	—			—			(207.0		)
	Total liabilities	$	(595.6	)	$	(347.9	)	$	(40.7	)	$	(207.0	)
		Balance at			Quoted Price in			Significant			Significant
		December 31, 2012			Active Markets for			Other Observable			Unobservable
					Identical Assets			Inputs			Inputs
					(Level 1)			(Level 2)			(Level 3)
	Assets:
	Available-for-sale securities	$	1,809.90		$	0.3		$	1,809.60		$	—
	Cash equivalents	27			—			27			—
	Interest rate swaps	1.7			—			1.7			—
	Forward currency contracts	17.8			—			17.8			—
	Purchased currency options	2.7			—			2.7			—
	Total assets	$	1,859.10		$	0.3		$	1,858.80		$	—
	Liabilities:
	Contingent value rights	$	(277.4	)	$	(277.4	)	$	—		$	—
	Written currency options	(5.1		)	—			(5.1		)	—
	Other acquisition related contingent consideration	(198.1		)	—			—			(198.1		)
	Total liabilities	$	(480.6	)	$	(277.4	)	$	(5.1	)	$	(198.1	)
	There were no security transfers between Levels 1 and 2 during the nine-month periods ended September 30, 2013 and 2012.  The following table represents a roll-forward of the fair value of Level 3 instruments (significant unobservable inputs):
		Nine-Month Periods Ended September 30,
		2013			2012
	Liabilities:
	Balance at beginning of period	$	(198.1	)	$	(76.9	)
	Amounts acquired or issued	—			(171.7		)
	Net change in fair value	(8.9		)	35.6
	Settlements	—			—
	Transfers in and/or out of Level 3	—			—
	Balance at end of period	$	(207.0	)	$	(213.0	)
	Level 3 liabilities issued during the nine-month period ended September 30, 2012 consisted of contingent consideration related to the acquisition of Avila.

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Activities

9 Months Ended

Sep. 30, 2013

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities

Derivative Instruments and Hedging Activities

Our revenue, earnings, cash flows and fair values of assets and liabilities can be impacted by fluctuations in foreign exchange rates and interest rates.  We actively manage the impact of foreign exchange rate and interest rate movements through operational means and through the use of various financial instruments, including derivative instruments such as foreign currency forward contracts, foreign currency option contracts, treasury rate lock agreements and interest rate swap contracts.

Foreign Currency Risk Management

We maintain a foreign exchange exposure management program to mitigate the impact of volatility in foreign exchange rates on future foreign currency cash flows, translation of foreign earnings and changes in the fair value of assets and liabilities denominated in foreign currencies.

Through our revenue hedging program, we endeavor to reduce the impact of possible unfavorable changes in foreign exchange rates on our future U.S. dollar cash flows that are derived from foreign currency denominated sales. To achieve this objective, we hedge a portion of our forecasted foreign currency denominated sales that are expected to occur in the foreseeable future, typically within the next three years.  We manage our anticipated transaction exposure principally with foreign currency forward contracts and occasionally foreign currency put and call options.

Foreign Currency Forward Contracts:  We use foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, manage exchange rate volatility in the translation of foreign earnings and reduce exposures to foreign currency fluctuations of certain assets and liabilities denominated in foreign currencies.

We manage a portfolio of foreign currency forward contracts to protect against changes in anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates, primarily associated with non-functional currency denominated revenues and expenses of foreign subsidiaries.  The foreign currency forward hedging contracts outstanding at September 30, 2013 and December 31, 2012 had settlement dates within 36 months.  These foreign currency forward contracts are designated as cash flow hedges and, to the extent effective, any unrealized gains or losses on them are reported in other comprehensive income (loss) (OCI) and reclassified to operations in the same periods during which the underlying hedged transactions affect operations.  Any ineffectiveness on these foreign currency forward contracts is reported in other income (expense), net.  Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows at September 30, 2013 and December 31, 2012:

Notional Amount

Foreign Currency

September 30, 2013

December 31, 2012

Australian Dollar

$

53.7

$

5.1

British Pound

313.8

77.9

Canadian Dollar

84.7

134.4

Euro

2,425.30

969.3

Japanese Yen

703.2

236.2

Total

$

3,580.70

$

1,422.90

We consider the impact of our own and the counterparties’ credit risk on the fair value of the contracts as well as the ability of each party to execute its obligations under the contract on an ongoing basis.  As of September 30, 2013, credit risk did not materially change the fair value of our foreign currency forward contracts.

We also manage a portfolio of foreign currency contracts to reduce exposures to foreign currency fluctuations of certain recognized assets and liabilities denominated in foreign currencies and, from time to time, we enter into foreign currency contracts to manage exposure related to translation of foreign earnings. These foreign currency forward contracts have not been designated as hedges and, accordingly, any changes in their fair value are recognized on the Consolidated Statements of Income in other income (expense), net in the current period.  The aggregate notional amount of the foreign currency forward non-designated hedging contracts outstanding at September 30, 2013 and December 31, 2012 were $816.1 million and $795.4 million, respectively.

Foreign Currency Option Contracts: We hedge a portion of our future foreign currency exposure by utilizing a strategy that involves both a purchased local currency put option and a written local currency call option that are accounted for as hedges of future sales denominated in euros.  Specifically, we sell (or write) a local currency call option and purchase a local currency put option with the same expiration dates and amounts but with different strike prices; this combination of transactions is generally referred to as a “collar”.  The expiration dates and notional amounts correspond to the amount and timing of forecasted future foreign currency sales.  If the U.S. dollar weakens relative to the currency of the hedged anticipated sales, the purchased put option value reduces to zero and we benefit from the increase in the U.S. dollar equivalent value of our anticipated foreign currency cash flows, however this benefit would be capped at the strike level of the written call, which forms the upper end of the collar.  The premium collected from the call option partially offsets the premium paid for the purchased put option, resulting in a net cost for the collars.

In order to fully offset the net cost of collars entered into to hedge sales, we sold local currency put options with a lower strike price and the same expiration dates and amounts as the option contracts included in the collars.  These written put options introduced risk of loss if the U.S. dollar were to strengthen beyond the strike price of the written put options.  We entered into purchased put options that were not designated as hedges in order to partially offset the risk of loss that would be incurred on the written put options if the US dollar were to strengthen beyond the strike price of the written put.  Gains and losses associated with the non-hedge put options have been recorded on the income statement as other income (expense), net.

Foreign currency option contracts entered into to hedge forecasted revenue and expenses were as follows at September 30, 2013 and December 31, 2012:

Notional Amount*

Foreign Currency Option

September 30, 2013

December 31, 2012

Designated as hedging activity:

Purchased Put

$

24.3

$

228.8

Written Call

$

25.4

$

235.9

Not designated as hedging activity:

Purchased Put

$

22.7

$

160.5

Written Put

$

(22.7

)

$

(216.0

)

* U.S. Dollar notional amounts are calculated as the hedged local currency amount multiplied times the strike value of the foreign currency option.  The local currency notional amounts of our purchased put and written call that are designated as hedging activity are equal to each other.

Interest Rate Risk Management

In anticipation of issuing fixed-rate debt, we may use forward starting interest rate swaps (forward starting swaps) or treasury rate lock agreements (treasury rate locks) that are designated as cash flow hedges to hedge against changes in interest rates that could impact expected future issuances of debt. To the extent these hedges of cash flows related to anticipated debt are effective, any realized or unrealized gains or losses on the treasury rate locks or forward starting swaps are reported in OCI and are recognized in income over the life of the anticipated fixed-rate notes.

Forward Starting Interest Rate Swaps: During September 2013 we entered into a forward starting swap, that was designated as a cash flow hedge, with a notional value of $100.0 million, an effective date in November 2014 and a maturity of ten years to hedge against changes in interest rates that could impact an anticipated issuance of debt. During October 2013, we entered into additional forward starting swaps with an effective date in November 2014 and an aggregate notional value of $150.0 million, consisting of $100 million with a five year maturity and $50 million with a ten year maturity.

Treasury Rate Lock Agreements:  During 2012, we entered into treasury rate locks in anticipation of issuing fixed-rate notes that were issued in August 2012.  The treasury rate locks were settled during 2012, resulting in losses of $35.3 million that were recorded to OCI.  No material amounts were recorded in income during the nine-month periods ended September 30, 2013 or 2012 as a result of hedge ineffectiveness or hedge components excluded from the assessment of effectiveness. We have not entered into any treasury rate locks during the nine months ended September 30, 2013 and at September 30, 2013 we had no outstanding treasury rate locks.

Interest Rate Swap Contracts:  From time to time we hedge the fair value of certain debt obligations through the use of interest rate swap contracts.  The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in interest rates.  Since the specific terms and notional amount of the swap are intended to match those of the debt being hedged, it is assumed to be a highly effective hedge and all changes in fair value of the swap are recorded on the Consolidated Balance Sheets with no net impact recorded in income.  Any net interest payments made or received on interest rate swap contracts are recognized as interest expense.  We may terminate the hedging relationship of certain swap contracts by settling the contracts or by entering into offsetting contracts.  At the time a hedging relationship is terminated, accumulated gains or losses associated with the swap contract are measured and recorded as a reduction of current and future interest expense associated with the previously hedged notes.

During the nine-month period ended September 30, 2013, we entered into swap contracts that were designated as hedges of our fixed rate notes due in 2015, 2017, 2018, 2020, 2022 and 2023 and also terminated the hedging relationship by settling certain of those swap contracts during the nine-month period ended September 30, 2013.  This resulted in net proceeds received of $21.9 million which is accounted for as a reduction of current and future interest expense associated with these notes.  See Note 11 for additional details related to reductions of current and future interest expense.

At September 30, 2013, we were a party to pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes.  The following table summarizes the notional amounts of our outstanding swap contracts at September 30, 2013 and December 31, 2012:

Notional Amount

September 30, 2013

December 31, 2012

Interest rate swap contracts entered into as fair value hedges of the following fixed-rate senior notes:

2.450% senior notes due 2015

$

300

$

—

1.900% senior notes due 2017

300

100

3.950% senior notes due 2020

500

—

3.250% senior notes due 2022

850

200

4.000% senior notes due 2023

50

—

Total

$

2,000.00

$

300

The following table summarizes the fair value and presentation in the Consolidated Balance Sheets for derivative instruments as of September 30, 2013 and December 31, 2012:

September 30, 2013

Asset Derivatives

Liability Derivatives

Instrument

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments:

Other current assets

$

62.6

Other current assets

$

24.7

Foreign exchange contracts*

Other current liabilities

35.2

Other current liabilities

70.5

Other non-current assets

31.4

Other non-current assets

19.5

Other non-current liabilities

0.9

Other non-current liabilities

17.4

Other current assets

11.4

Other current assets

—

Interest rate swap agreements

Other non-current assets

0.3

Other non-current assets

—

Other non-current liabilities

—

Other non-current liabilities

44.8

Derivatives not designated as hedging instruments:

Foreign exchange contracts*

Other current assets

20

Other current assets

6.2

Other current liabilities

5.5

Other current liabilities

27.5

Other non-current assets

1.1

Other non-current assets

—

Interest rate swap agreements

Other non-current assets

1.6

Other non-current assets

—

Total

$

170

$

210.6

December 31, 2012

Asset Derivatives

Liability Derivatives

Instrument

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments:

Other current assets

$

35.2

Other current assets

$

12.7

Foreign exchange contracts*

Other current liabilities

9.1

Other current liabilities

31.4

Other non-current assets

30.5

Other non-current assets

13.8

Other current assets

0.1

Other current assets

—

Interest rate swap agreements

Other non-current assets

0.1

Other non-current assets

0.2

Other non-current liabilities

—

Other non-current liabilities

0.6

Derivatives not designated as hedging instruments:

Foreign exchange contracts*

Other current assets

45.8

Other current assets

36.3

Other current liabilities

10.4

Other current liabilities

21.4

Interest rate swap agreements

Other current assets

0.6

Other current assets

—

Other non-current assets

1.7

Other non-current assets

—

Total

$

133.5

$

116.4

* Derivative instruments in this category are subject to master netting arrangements and are presented on a net basis in the Consolidated Balance Sheets in accordance with ASC 210-20.

The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments on the Consolidated Statements of Income for the three- and nine-month periods ended September 30, 2013 and 2012:

Three-Month Period Ended September 30, 2013

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Recognized in OCI

Reclassified from

Reclassified from

Recognized in

Recognized in

on Derivative (1)

Accumulated OCI

Accumulated OCI

Income on

Income on

into Income

into Income

Derivative

Derivative

Instrument

(Effective Portion)

(Effective Portion)

(Effective Portion)

(Ineffective Portion

(Ineffective Portion

and Amount Excluded

and Amount Excluded

From Effectiveness

From Effectiveness

Testing)

Testing)

Foreign exchange contracts

$

(89.8

)

Net product sales

$

11.9

Other income, net

$

5.1

-2

Treasury rate lock agreements

$

—

Interest expense

$

(0.9

)

(1) Net losses of $1.9 million are expected to be reclassified from Accumulated OCI into income in the next 12 months.

(2) The amount of net gains recognized in income represents $5.3 million of gains related to amounts excluded from the assessment of hedge effectiveness and $0.2 million of losses related to the ineffective portion of the hedging relationships.

Three-Month Period Ended September 30, 2012

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Recognized in OCI

Reclassified from

Reclassified from

Recognized in

Recognized in

on Derivative

Accumulated OCI

Accumulated OCI

Income on

Income on

into Income

into Income

Derivative

Derivative

Instrument

(Effective Portion)

(Effective Portion)

(Effective Portion)

(Ineffective Portion

(Ineffective Portion

and Amount Excluded

and Amount Excluded

From Effectiveness

From Effectiveness

Testing)

Testing)

Foreign exchange contracts

$

(24.5

)

Net product sales

$

24.8

Other income, net

$

(1.7

)

-1

Treasury rate lock agreements

$

(3.5

)

Interest expense

$

(0.5

)

(1) The amount of net losses recognized in income represents $2.2 million in losses related to the ineffective portion of the hedging relationships and $0.5 million of gains related to amounts excluded from the assessment of hedge effectiveness.

Nine-Month Period Ended September 30, 2013

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Recognized in OCI

Reclassified from

Reclassified from

Recognized in

Recognized in

on Derivative

Accumulated OCI

Accumulated OCI

Income on

Income on

into Income

into Income

Derivative

Derivative

Instrument

(Effective Portion)

(Effective Portion)

(Effective Portion)

(Ineffective Portion

(Ineffective Portion

and Amount Excluded

and Amount Excluded

From Effectiveness

From Effectiveness

Testing)

Testing)

Foreign exchange contracts

$

(3.2

)

Net product sales

$

7.6

Other income, net

$

9

(1

)

Treasury rate lock agreements

$

—

Interest expense

$

(2.5

)

(1) The amount of net gains recognized in income represents $1.7 million in gains related to the ineffective portion of the hedging relationships and $7.3 million of gains related to amounts excluded from the assessment of hedge effectiveness.

Nine-Month Period Ended September 30, 2012

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Recognized in OCI

Reclassified from

Reclassified from

Recognized in

Recognized in

on Derivative

Accumulated OCI

Accumulated OCI

Income on

Income on

into Income

into Income

Derivative

Derivative

Instrument

(Effective Portion)

(Effective Portion)

(Effective Portion)

(Ineffective Portion

(Ineffective Portion

and Amount Excluded

and Amount Excluded

From Effectiveness

From Effectiveness

Testing)

Testing)

Foreign exchange contracts

$

43.3

Net product sales

$

62.8

Other income, net

$

(3.4

)

-1

Treasury rate lock agreements

$

(35.3

)

Interest expense

$

(0.5

)

(1) The amount of net losses recognized in income represents $7.5 million in losses related to the ineffective portion of the hedging relationships and $4.1 million of gains related to amounts excluded from the assessment of hedge effectiveness.

The following table summarizes the effect of derivative instruments designated as fair value hedging instruments on the Consolidated Statements of Income for the three- and nine-month periods ended September 30, 2013 and 2012:

Amount of Gain (Loss) Recognized in

Income on Derivative

Location of Gain (Loss) Recognized in Income

Three-Month Periods Ended September 30,

Nine-Month Periods Ended September 30,

Instrument

on Derivative

2013

2012

2013

2012

Interest rate swap agreements

Interest expense

$

9.8

$

2

$

21.8

$

5.6

The following table summarizes the effect of derivative instruments not designated as hedging instruments on the Consolidated Statements of Income for the three- and nine-month periods ended September 30, 2013 and 2012:

Amount of Gain (Loss) Recognized in

Income on Derivative

Location of Gain (Loss) Recognized in Income

Three-Month Periods Ended September 30,

Nine-Month Periods Ended September 30,

Instrument

on Derivative

2013

2012

2013

2012

Foreign exchange contracts

Other income, net

$

(27.0

)

$

(11.5

)

$

(42.2

)

$

4.5

Treasury rate lock agreements

Other income, net

$

—

$

—

$

—

$

3.7

The impact of gains and losses on foreign exchange contracts not designated as hedging instruments related to changes in the fair value of assets and liabilities denominated in foreign currencies are generally offset by net foreign exchange gains and losses, which are also included in other income (expense), net for all periods presented. When we enter into foreign exchange contracts not designated as hedging instruments to mitigate the impact of exchange rate volatility in the translation of foreign earnings, gains and losses will generally be offset by fluctuations in the U.S. Dollar translated amounts of each Income Statement account in current and/or future periods.

Cash_Cash_Equivalents_and_Mark

Cash, Cash Equivalents and Marketable Securities Available-for-Sale	9 Months Ended
	Sep. 30, 2013
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash, Cash Equivalents and Marketable Securities Available-for-Sale	Cash, Cash Equivalents and Marketable Securities Available-for-Sale
	Money market funds of $860.4 million and $1.160 billion at September 30, 2013 and December 31, 2012, respectively, were recorded at cost, which approximates fair value and are included in cash and cash equivalents.
	The amortized cost, gross unrealized holding gains, gross unrealized holding losses and estimated fair value of available-for-sale securities by major security type and class of security at September 30, 2013 and December 31, 2012 were as follows:
	September 30, 2013	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss			Estimated Fair Value
	U.S. Treasury securities	$	1,017.20	$	0.7	$	—		$	1,017.90
	U.S. government-sponsored agency securities	400.1		0.2		(0.9		)	399.4
	U.S. government-sponsored agency MBS	587.1		0.5		(7.9		)	579.7
	Non-U.S. government, agency and Supranational securities	74.2		—		(0.1		)	74.1
	Corporate debt - global	701.8		0.9		(1.2		)	701.5
	Asset backed securities	229.6		0.1		(0.3		)	229.4
	Marketable equity securities	190.7		231.6		—			422.3
	Total available-for-sale marketable securities	$	3,200.70	$	234	$	(10.4	)	$	3,424.30
	December 31, 2012	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss			Estimated Fair Value
	U.S. Treasury securities	$	902	$	0.5	$	—		$	902.5
	U.S. government-sponsored agency securities	303.5		0.3		—			303.8
	U.S. government-sponsored agency MBS	387.2		1.6		(1.8		)	387
	Non-U.S. government, agency and Supranational securities	7.1		—		—			7.1
	Corporate debt - global	208.5		0.9		(0.2		)	209.2
	Marketable equity securities	0.4		—		(0.1		)	0.3
	Total available-for-sale marketable securities	$	1,808.70	$	3.3	$	(2.1	)	$	1,809.90
	U.S. government-sponsored agency securities include general unsecured obligations either issued directly by or guaranteed by U.S. Government Sponsored Enterprises.  U.S. government-sponsored agency mortgage-backed securities (MBS) include mortgage-backed securities issued by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation and the Government National Mortgage Association.  Non-U.S. government, agency and Supranational securities consist of direct obligations of highly rated governments of nations other than the United States and obligations of sponsored agencies and other entities that are guaranteed or supported by highly rated governments of nations other than the United States.  Corporate debt-global includes obligations issued by investment-grade corporations, including some issues that have been guaranteed by governments and government agencies.  Asset backed securities consist of triple-A rated securities with cash flows collateralized by credit card receivables and auto loans. Marketable equity securities consist of investments in equity securities that have become publicly traded.  The increase in net unrealized gains in marketable equity securities during the nine-month period ended September 30, 2013 primarily reflects the increase in market value for certain equity investments subsequent to their respective initial public offerings. Net unrealized losses in the marketable debt securities primarily reflect the impact of increased interest rates at September 30, 2013.
	Duration periods of available-for-sale debt securities at September 30, 2013 were as follows:
		Amortized		Fair
		Cost		Value
	Duration of one year or less	$	1,370.40	$	1,369.30
	Duration of one through three years	1,419.00		1,415.70
	Duration of three through five years	203.7		200.4
	Duration of over five years	16.9		16.6
	Total	$	3,010.00	$	3,002.00

Inventory

Inventory	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]
Inventory	Inventory
	A summary of inventories by major category at September 30, 2013 and December 31, 2012 follows:
		September 30, 2013		December 31, 2012
	Raw materials	$	125.7	$	79.2
	Work in process	96.4		86.5
	Finished goods	91.2		93.8
	Total	$	313.3	$	259.5

Intangible_Assets_and_Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets and Goodwill
	Intangible Assets:  Our intangible assets consist of developed product rights obtained primarily from the Pharmion, Gloucester and Abraxis acquisitions, in-process research and development (IPR&D) product rights from the Gloucester and Avila acquisitions and technology obtained primarily from the Avila acquisition. Also included are contract-based licenses and other miscellaneous intangibles.  The amortization periods related to our finite-lived intangible assets range from one to 17 years.  The following summary of intangible assets by category includes intangibles currently being amortized and intangibles not yet subject to amortization:
	September 30, 2013		Gross Carrying Value		Accumulated Amortization			Intangible Assets, Net		Weighted Average Life (Years)
	Amortizable intangible assets:
	Acquired developed product rights		$	3,405.90	$	(973.4	)	$	2,432.50	13
	Technology		333.7		(75.5		)	258.2		7
	Licenses		66.2		(12.9		)	53.3		16.5
	Other		45		(18.7		)	26.3		8.3
			3,850.80		(1,080.5		)	2,770.30		12.5
	Non-amortized intangible assets:
	Acquired IPR&D product rights		137.9		—			137.9
	Total intangible assets		$	3,988.70	$	(1,080.5	)	$	2,908.20
	December 31, 2012		Gross Carrying Value		Accumulated Amortization			Intangible Assets, Net		Weighted Average Life (Years)
	Amortizable intangible assets:
	Acquired developed product rights		$	3,400.40	$	(814.5	)	$	2,585.90	13
	Technology		333.3		(39.8		)	293.5		7
	Licenses		64.3		(10.0		)	54.3		16.8
	Other		43.4		(14.6		)	28.8		8.5
			3,841.40		(878.9		)	2,962.50		12.5
	Non-amortized intangible assets:
	Acquired IPR&D product rights		137.9		—			137.9
	Total intangible assets		$	3,979.30	$	(878.9	)	$	3,100.40
	The gross carrying value of intangible assets increased by $9.4 million at September 30, 2013 compared to December 31, 2012 primarily resulting from the acquisition of $5.5 million in developed product rights and $3.9 million from other miscellaneous agreements.
	Amortization expense was $67.5 million and $46.4 million for the three-month periods ended September 30, 2013 and 2012, respectively, and $201.6 million and $133.0 million for the nine-month periods ended September 30, 2013 and 2012, respectively.  The increases in amortization expense in the quarter and year-to-date periods ended September 30, 2013 were primarily due to the October 2012 approval of ABRAXANE® in the U.S. for the treatment of non-small cell lung cancer (NSCLC) which resulted in the commencement of amortization of the related intangible asset and an increase in amortization of technology related to the March 7, 2012 acquisition of Avila and its Avilomics™ platform.  Assuming no changes in the gross carrying amount of intangible assets, the amortization of intangible assets for years 2013 through 2017 is estimated to be in the range of approximately $255.0 million to $270.0 million annually.
	Goodwill:  At September 30, 2013, our goodwill related to the 2012 acquisition of Avila, the 2010 acquisitions of Abraxis and Gloucester, the 2008 acquisition of Pharmion and the 2004 acquisition of Penn T Limited.
	The change in carrying value of goodwill is summarized as follows:
	Balance at December 31, 2012	$	2,042.80
	Tax benefit on the exercise of Pharmion converted stock options	(0.7		)
	Balance at September 30, 2013	$	2,042.10

Debt

Debt	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]
Debt	Debt
	Senior Notes: Summarized below are the carrying values of our senior notes at September 30, 2013 and December 31, 2012:
		September 30, 2013		December 31, 2012
	2.450% senior notes due 2015	$	515.7	$	520.1
	1.900% senior notes due 2017	500.8		500.6
	2.300% senior notes due 2018	400.1		—
	3.950% senior notes due 2020	492.4		499
	3.250% senior notes due 2022	975		1,002.10
	4.000% senior notes due 2023	698.1		—
	5.700% senior notes due 2040	249.6		249.5
	5.250% senior notes due 2043	396.6		—
	Total long-term debt	$	4,228.30	$	2,771.30
	At September 30, 2013, the fair value of our outstanding Senior Notes was $4.252 billion and represented a Level 2 measurement within the fair value measurement hierarchy.
	In August 2013, we issued an additional $1.500 billion principal amount of senior notes consisting of $400.0 million aggregate principal amount of 2.300% Senior Notes due 2018 (the 2018 notes), $700.0 million aggregate principal amount of 4.000% Senior Notes due 2023 (the 2023 notes) and $400.0 million aggregate principal amount of 5.250% Senior Notes due 2043 (the 2043 notes) and, together with the 2018 notes and 2023 notes, referred to herein as the “2013 issued notes”. The 2013 issued notes were issued at 99.792%, 99.452% and 99.147% of par, respectively, and the discount is being amortized as additional interest expense over the period from issuance through maturity. Offering costs of approximately $12.5 million have been recorded as debt issuance costs on our Consolidated Balance Sheets and are being amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. Interest on the notes is payable semi-annually in arrears on February 15 and August 15 each year beginning February 15, 2014 and the principal on each note is due in full at their respective maturity dates. The notes may be redeemed at our option, in whole or in part, at any time at a redemption price defined in a make-whole clause equaling accrued and unpaid interest plus the greater of 100% of the principal amount of the notes to be redeemed or the sum of the present values of the remaining scheduled payments of interest and principal discounted to the date of redemption on a semi-annual basis plus 15 basis points in the case of the 2018 notes, 20 basis points in the case of the 2023 notes and 25 basis points in the case of the 2043 notes. If we experience a change of control accompanied by a downgrade of the debt to below investment grade, we will be required to offer to repurchase the notes at a purchase price equal to 101% of their principal amount plus accrued and unpaid interest. We are subject to covenants which limit our ability to pledge properties as security under borrowing arrangements and limit our ability to perform sale and leaseback transactions involving our property.
	During 2012, we entered into treasury rate locks in anticipation of issuing the fixed-rate notes that were issued in August 2012.  As of September 30, 2013, a balance of $31.4 million in losses remained in OCI related to treasury rate locks and will be recognized as interest expense over the life of the 2017 notes and the 2022 notes.
	At September 30, 2013, we were party to pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes as described in Note 7.  Our swap contracts outstanding at September 30, 2013 effectively convert the hedged portion of our fixed-rate notes to floating rates.  From time to time we terminate the hedging relationship on certain of our swap contracts by settling the contracts or by entering into offsetting contracts.  Any net proceeds received or paid in these settlements are accounted for as a reduction or increase of current and future interest expense associated with the previously hedged notes.  As of September 30, 2013, we had a balance of $33.8 million of gains recorded as a reduction of our debt as a result of past swap contract settlements, including $14.7 million related to the settlement of swap contracts during the nine months ended September 30, 2013.
	Commercial Paper:  The maximum aggregate amount available under our Commercial Paper program was increased by $500.0 million to $1.500 billion in May 2013. The carrying value of Commercial Paper as of September 30, 2013 and December 31, 2012 was $405.9 million and $308.5 million, respectively, and approximated its fair value.  The effective interest rate on our outstanding Commercial Paper at September 30, 2013 was 0.3%.
	Senior Unsecured Credit Facility:  We maintain a senior unsecured revolving credit facility (Credit Facility) that provides revolving credit in the aggregate amount of $1.500 billion, which was increased from $1.000 billion in April 2013. During April 2013, the term of the Credit Facility was also extended from September 2, 2016 to April 18, 2018.   Subject to certain conditions, we have the right to increase the amount of the Credit Facility (but in no event more than one time per annum) up to a maximum aggregate amount of $1.750 billion.  Amounts may be borrowed in U.S. dollars for working capital, capital expenditures and other corporate purposes. The Credit Facility currently serves as backup liquidity for our Commercial Paper borrowings.  At September 30, 2013 and December 31, 2012, there was no outstanding borrowing against the Credit Facility.
	The Credit Facility contains affirmative and negative covenants including certain customary financial covenants.  We were in compliance with all financial covenants as of September 30, 2013.

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation
	We have a stockholder-approved stock incentive plan, the 2008 Stock Incentive Plan (Amended and Restated as of April 17, 2013) (Plan) which provides for the granting of options, restricted stock awards (RSUs), stock appreciation rights, performance awards (PSUs) and other share-based awards to our employees and officers.  The Management Compensation and Development Committee of the Board of Directors (Compensation Committee) may determine the type, amount and terms, including vesting, of any awards made under the Plan.
	On June 12, 2013, our stockholders approved an amendment and restatement of the Plan, which included the following key modifications: adoption of an aggregate share reserve of 104,981,641 shares of Common Stock, which includes 9,000,000 new shares of Common Stock; increase in the maximum payment to an eligible employee under a cash-based performance award from $4.0 million to $6.0 million; and extension of the term of the plan through April 17, 2023.
	The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Income for the three- and nine-month periods ended September 30, 2013 and 2012:
		Three-Month Periods Ended							Nine-Month Periods Ended
		September 30,							September 30,
		2013			2012				2013		2012
	Cost of goods sold (excluding amortization of acquired intangible assets)	$	6.1		$	3.3			$	12.6	$	9.2
	Research and development	41.7			27.2				100.5		75.8
	Selling, general and administrative	44.2			32.1				114.3		86
	Total share-based compensation expense	92			62.6				227.4		171
	Tax benefit related to share-based compensation expense	29.9			17				66.1		45.7
	Reduction in income	$	62.1		$	45.6			$	161.3	$	125.3
	Share-based compensation cost included in inventory was $1.7 million and $1.2 million at September 30, 2013 and December 31, 2012, respectively.
	We utilize share-based compensation in the form of stock options, RSUs and PSUs.  The following table summarizes the activity for stock options, RSUs and PSUs for the nine-month period ended September 30, 2013 (in thousands):
		Stock		Restricted			Performance-
		Options		Stock			Based Restricted
				Units			Stock
							Units
	Outstanding at December 31, 2012	42,592		4,463			26
	Changes during the Year:
	Granted	6,639		1,517			45
	Exercised / Released	(9,951	)	(832	)		(6	)
	Forfeited	(863	)	(173	)		(8	)
	Expired	(36	)	N/A			N/A
	Outstanding at September 30, 2013	38,381		4,975			57
	Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2013 were as follows (dollars in millions):
		Stock			Restricted				Performance-
		Options			Stock				Based Restricted
					Units				Stock Units
	Unrecognized compensation cost	$	369.7		$	243.6			$	4.4
	Expected weighted-average period in years of compensation cost to be recognized	2.2			1.6				1.8

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	We regularly evaluate the likelihood of the realization of our deferred tax assets and reduce the carrying amount of those deferred tax assets by a valuation allowance to the extent we believe a portion will not be realized.  We consider many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income, the carryforward periods available to us for tax reporting purposes and other relevant factors.  Significant judgment is required in making this assessment.
	We operate under an income tax holiday in Switzerland that exempts us from Swiss income taxes on most of our operations in Switzerland through the end of 2015. In September 2013, we entered into a new tax holiday agreement with the Swiss tax authorities which reflects the planned expansion of our Swiss operations and will result in substantially similar Swiss tax benefits through the end of 2024. The new tax holiday is not expected to have a material impact on our 2013 financial statements.
	Our tax returns are under routine examination in many taxing jurisdictions.  The scope of these examinations includes, but is not limited to, the review of our taxable presence in a jurisdiction, our deduction of certain items, our claims for research and development credits, our compliance with transfer pricing rules and regulations and the inclusion or exclusion of amounts from our tax returns as filed.   Our U.S. federal income tax returns have been audited by the IRS through the year ended December 31, 2008. Tax returns for the years ended December 31, 2009, 2010 and 2011 are currently under examination by the IRS.  We are also subject to audits by various state and foreign taxing authorities, including, but not limited to, most U.S. states and major European and Asian countries where we have operations.
	We regularly reevaluate our tax positions and the associated interest and penalties, if applicable, resulting from audits of federal, state and foreign income tax filings, as well as changes in tax law (including regulations, administrative pronouncements, judicial precedents, etc.) that would reduce the technical merits of the position to below more likely than not. We believe that our accruals for tax liabilities are adequate for all open years. Many factors are considered in making these evaluations, including past history, recent interpretations of tax law and the specifics of each matter. Because tax regulations are subject to interpretation and tax litigation is inherently uncertain, these evaluations can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. We apply a variety of methodologies in making these estimates and assumptions, which include studies performed by independent economists, advice from industry and subject experts, evaluation of public actions taken by the IRS and other taxing authorities, as well as our industry experience.  These evaluations are based on estimates and assumptions that have been deemed reasonable by management.  However, if management’s estimates are not representative of actual outcomes, our results of operations could be materially impacted.
	Unrecognized tax benefits, generally represented by liabilities on the consolidated balance sheet and all subject to tax examinations, arise when the estimated benefit recorded in the financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above.  These unrecognized tax benefits relate primarily to issues common among multinational corporations.  Virtually all of these unrecognized tax benefits, if recognized, would impact the effective income tax rate.  We account for interest and potential penalties related to uncertain tax positions as part of our provision for income taxes. For the nine-month period ended September 30, 2013 gross unrecognized tax benefits decreased by $2.2 million, exclusive of interest, as a result of net settlements and ongoing examinations related to tax positions taken in prior years. Increases to the amount of unrecognized tax benefits since January 1, 2013 of approximately $23.6 million relate primarily to current year operations.  The liability for unrecognized tax benefits is expected to increase in the next 12 months relating to operations occurring in that period.  Any settlements of examinations with taxing authorities or statute of limitations expirations would likely result in a significant decrease in our unrecognized tax benefits.  Our estimates of tax benefits and potential tax benefits may not be representative of actual outcomes and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire.

Collaboration_Agreements

Collaboration Agreements	9 Months Ended
	Sep. 30, 2013
Collaboration Agreements
Collaboration Agreements	Collaboration Agreements
	From time to time, we enter into collaborative arrangements, for the research and development, license, manufacture and/or commercialization of products and/or product candidates.  In addition, we also acquire product and research and development technology rights and establish research and development collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our research and development capabilities, product pipeline and marketed product base. These arrangements may include non-refundable, upfront payments, option payments for the purchase or license of additional rights, development, regulatory and commercial performance milestone payments, cost sharing arrangements, royalty payments and profit sharing. Certain of these arrangements obligate us to make additional equity investments in the event of an initial public offering of equity by our partners. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success.  We do not consider any individual arrangement to be material.  See Note 17 of Notes to Consolidated Financial Statements included in our 2012 Annual Report on Form 10-K for a description of certain other collaboration agreements entered into prior to January 1, 2013.  The following is a brief description of certain collaborations entered into during the nine months ended September 30, 2013:
	bluebird bio, Inc.:  On March 19, 2013, we entered into a collaboration agreement with bluebird bio, Inc. (bluebird) to discover, develop and commercialize novel disease-altering gene therapies in oncology. The collaboration focuses on applying gene therapy technology to modify a patient’s own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells. The collaboration has the potential to lead to the development of multiple CAR T-cell products. Under the agreement, we have an option to license any products resulting from the collaboration after the completion of a phase I clinical study by bluebird for each such product.
	The financial terms of the agreement include an upfront payment and up to $225.0 million per product in aggregate potential option fees and clinical and regulatory milestones. bluebird also has the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and profit share in the United States in exchange for a reduction of milestone payments. Royalties would also be paid to bluebird in regions where there is no profit share, including in the United States if bluebird declines to exercise their co-development and profit sharing rights.
	The agreement has a termination date of March 19, 2016 and we have the right to unilaterally extend the agreement until March 19, 2019 with the payment of extension fees.  Further, we have the ability to terminate the collaboration at our discretion upon 90 days written notice to bluebird.  If a product is optioned, the parties will enter into a pre-negotiated license agreement and potentially a co-development agreement should bluebird exercise its right to participate in the development and commercialization in the United States.  The license agreement, if not terminated sooner, would expire upon the expiration of all applicable royalty terms under the agreement with respect to the particular product and the co-development agreement, if not terminated sooner, would expire when the product is no longer being developed or commercialized in the United States.  Upon the expiration of a particular license agreement, we will have a fully paid-up, royalty-free license to use bluebird intellectual property to manufacture, market, use and sell such licensed product developed under the agreement.
	FORMA Therapeutics Holdings, LLC: On April 19, 2013, we entered into a collaboration agreement with FORMA Therapeutics Holdings, LLC (FORMA) under which the parties will discover, develop and commercialize drug candidates to regulate protein homeostasis targets. Protein homeostasis, which is important in oncology, neurodegenerative and other disorders, involves a tightly regulated network of pathways controlling the biogenesis, folding, transport and degradation of proteins.
	The collaboration was launched with an upfront payment that enables us to evaluate selected targets and lead assets in protein homeostasis pathways during the pre-clinical phase. Based on such evaluation, we will have the right to obtain exclusive licenses with respect to the development and commercialization of multiple drug candidates outside of the United States, in exchange for research and early development payments of up to approximately $200.0 million to FORMA. Under the terms of the collaboration agreement, FORMA is incentivized to advance the full complement of drug candidates through Phase I, while Celgene will be responsible for all further global clinical development for each licensed candidate.  FORMA is eligible to receive up to an additional $315.0 million in potential payments based upon development, regulatory and sales objectives for the first ex-U.S. license. FORMA is also eligible to receive potential payments for successive licenses, which escalate for productivity, increasing up to a maximum of an additional $430.0 million per program.  In addition, FORMA will receive royalties on ex-U.S. sales and additional payments if multiple drug candidates reach defined cumulative sales objectives. The collaboration agreement includes provisions for Celgene to obtain rights with respect to development and commercialization of drug candidates inside the United States in exchange for additional payments.
	Under the collaboration, the parties will perform initial research and development for a term of four years. If, during such research term, a drug candidate meets certain criteria, then the parties will enter into a pre-negotiated license agreement and the collaboration will continue until all license agreements have expired and all applicable royalty terms under the collaboration with respect to the particular products have expired. Each license agreement, if not terminated sooner, would expire upon the expiration of all applicable royalty terms under such agreement. Upon the expiration of each license agreement, we will have an exclusive, fully-paid, royalty-free license to use the applicable FORMA intellectual property to manufacture, market, use and sell the product developed under such agreement outside of the United States. On October 7, 2013, we entered into the first ex-US license with FORMA and paid the applicable upfront payment under such license.
	MorphoSys AG:  On June 26, 2013, we signed a collaboration, license and equity purchase agreement with MorphoSys AG (MorphoSys) to jointly develop MOR202 globally and to co-promote MOR202 in Europe.  On August 10, 2013, the transaction became effective.  MOR202 is a fully human monoclonal antibody targeting CD38 to treat patients with multiple myeloma and certain leukemias.  MOR202 is currently being evaluated in a phase I/IIa trial in patients with relapsed/refractory multiple myeloma.
	The financial terms of the transaction include an initial payment of EUR 117.0 million (approximately $152.1 million) that includes an upfront payment and an equity investment for 797,150 new shares of MorphoSys.  In addition, MorphoSys could receive up to EUR 511.0 million (approximately $664.5 million) in development, regulatory and sales milestones and tiered royalties on net sales of MOR202 outside the co-promotion territory.  In the co-promotion territory, MorphoSys retains a 50/50 profit sharing right on MOR202 in exchange for paying one third of the MOR202 development costs. Should MorphoSys choose to opt out of its co-promotion rights, MorphoSys would receive tiered royalties on net sales of MOR202 globally.
	The agreement may be terminated at our discretion upon six months written notice to MorphoSys, or by either party upon material breach of the other party. Upon the expiration of the agreement, we will have a fully paid-up, irrevocable, perpetual, non-terminable license to use the intellectual property licensed from MorphoSys to research, develop, make, commercialize, use and sell MOR202.
	Acetylon Pharmaceuticals, Inc.: On July 26, 2013, we entered into a strategic collaboration and option agreement with Acetylon Pharmaceuticals, Inc. (Acetylon). Under the agreement, the parties will support the development of Acetylon's portfolio of oral, selective HDAC inhibitors in oncology, hematology, immunology and neurologic disease indications. In addition, we have rights to receive certain research and development services from Acetylon and an exclusive right to acquire Acetylon at a later date at a purchase price based upon future independent company valuations.
	The collaboration focuses on the continued clinical advancement of Acetylon's lead candidate, ACY-1215, an HDAC6 inhibitor being developed for hematological malignancies, ACY-738 for neurological diseases, an HDAC1/2 inhibitor and a yet unnamed project, spanning cancer and non-cancer disease indications. Under the agreement, we made an upfront $100.0 million cash payment to Acetylon, which payment included an upfront fee for entering into the collaboration, fees for the exclusive right to acquire Acetylon and the rights to receive certain research and development services from Acetylon. During the term of the agreement, Acetylon will retain control of its drug development programs. If we exercise our right to acquire Acetylon, in addition to the purchase price based upon independent company valuations to be paid at the time of the acquisition, Acetylon shareholders will be eligible to receive potential future milestone payments for either approvals of, or additional indications of, drugs developed by Acetylon and for accomplishing defined sales targets. If all the milestones are achieved, the aggregate amount of the milestone payments would be $1.100 billion.
	The agreement has an expiration date of December 31, 2015 and we have the right to unilaterally extend the agreement until either June 30, 2016 or December 31, 2016 with the payment of an extension fee. Further, we have the ability to terminate the agreement at our discretion upon written notice to Acetylon.
	In addition to the collaboration arrangements described above, we entered into a number of collaborative arrangements during the nine months ended September 30, 2013 that resulted in $12.0 million of assets for investments in equity or other assets.  These additional collaboration arrangements include the potential for future milestone payments of up to an aggregate $373.0 million related to the attainment of specified development and regulatory approval milestones over a period of several years.  Our obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events which could cause the discontinuance of the programs.
	Upfront payments to all collaboration partners during the three- and nine-month periods ended September 30, 2013 resulted in research and development expenses of $171.3 million and $348.8 million, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Other Commitments: In conjunction with a September 2013 equity investment, the parent company of NantHealth LLC assumed, and agreed to pay and satisfy when due, our obligation to pay The Chan Soon-Shiong Institute for Advanced Health (CSS Institute) a $25.0 million contingent, milestone-based contribution.
	Collaboration Arrangements:  We have entered into certain research and development collaboration agreements with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial targets.  Our obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events which could cause the discontinuance of the programs.  Due to the nature and uncertainty of these arrangements and any future potential payments, no amounts have been recorded in our accompanying Consolidated Balance Sheets at September 30, 2013 and December 31, 2012.
	Contingencies:  We believe we maintain insurance coverage adequate for our current needs.  Our operations are subject to environmental laws and regulations, which impose limitations on the discharge of pollutants into the air and water and establish standards for the treatment, storage and disposal of solid and hazardous wastes.  We review the effects of such laws and regulations on our operations and modify our operations as appropriate.  We believe we are in substantial compliance with all applicable environmental laws and regulations. We have ongoing customs, duties and VAT examinations in various countries that have yet to be settled. Based on our knowledge of the claims and facts and circumstances to date, none of these matters, individually or in the aggregate, are deemed to be material to our financial condition.

Legal_Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2013
Legal Proceedings
Legal Proceedings	Legal Proceedings
	We and certain of our subsidiaries are involved in various patent, trademark, commercial and other claims; government investigations; and other legal proceedings that arise from time to time in the ordinary course of business.  Like many companies in our industry, we have from time to time received inquiries and subpoenas and other types of information requests from government authorities and we have been subject to claims and other actions related to our business activities.  While the ultimate outcome of investigations and legal proceedings are difficult to predict, adverse resolutions or settlements of those matters may result in, among other things, modification of our business practices, product recalls, incurrence of costs and payment of significant penalties, which may have a material adverse effect on our results of operations, cash flows or financial condition.
	Pending patent proceedings include challenges to the scope, validity or enforceability of our patents relating to certain of our products or processes. Although we believe we have substantial defenses to these challenges with respect to all our material patents, there can be no assurance as to the outcome of these matters and a loss in any of these proceedings could result in a loss of patent protection for the drug at issue, which could lead to a significant loss of sales of that product and could materially affect future results of operations.
	Among the principal matters pending are the following:
	In the fourth quarter of 2009, we received a Civil Investigative Demand (CID) from the U.S. Federal Trade Commission (FTC). The FTC requested documents and other information relating to requests by generic companies to purchase our patented REVLIMID® and THALOMID® brand drugs in order for the FTC to evaluate whether there is reason to believe that we have engaged in unfair methods of competition.  In the first quarter of 2010, the State of Connecticut referenced the same issues as those referenced in the 2009 CID and issued a subpoena. In the fourth quarter of 2010, we received a second CID from the FTC relating to this matter.  We continue to cooperate with the FTC and State of Connecticut investigations.
	In the first quarter of 2011, the United States Attorney’s Office for the Central District of California informed us that they are investigating possible off-label marketing and improper payments to physicians in connection with the sales of THALOMID® and REVLIMID®.  In the third quarter of 2012, we learned that two other United States Attorneys’ offices (the Northern District of Alabama and the Eastern District of Texas) and various state Attorneys General are conducting related investigations.  We are cooperating with these investigations.
	On June 7, 2013, Children's Medical Center Corporation (CMCC) filed a lawsuit against us in the Superior Court of the Commonwealth of Massachusetts.  CMCC alleges that our obligation under a license agreement relating to certain thalidomide analog patents entered into in December 2002 to pay a 1% royalty on REVLIMID® net sales revenue and a 2.5% royalty on POMALYST®/IMNOVID® net sales revenue extends beyond February 28, 2013 and that our failure to make royalty payments to CMCC with respect to REVLIMID® and POMALYST®/IMNOVID® subsequent to February 28, 2013 breached the license agreement.  We disagree with CMCC's allegations.  CMCC is seeking an unspecified amount of damages and a declaration that the license agreement remains in full force and effect.  In July 2013, we removed these proceedings to the Federal District Court for the District of Massachusetts. We intend to vigorously defend against CMCC's claims.  We do not believe that the ultimate outcome of this proceeding will have a material adverse impact on our financial condition.
	REVLIMID®: We had previously announced that we received a Notice Letter dated August 30, 2010, from Natco Pharma Limited of India (Natco) notifying us of Natco’s Abbreviated New Drug Application (ANDA), which contains Paragraph IV certifications against certain of Celgene’s patents that are listed in the FDA Approved Drug Products With Therapeutic Equivalence Evaluations (the “Orange Book”) for REVLIMID® (lenalidomide).  Under the Hatch-Waxman Act of 1984, a generic manufacturer may file an ANDA containing a certification (a “Paragraph IV certification”) challenging the validity or infringement of a patent listed in the Orange Book.  Natco’s Notice letter alleges, among other things, that certain claims of United States Patent Nos. 5,635,517 (the “’517 patent”), 6,045,501 (the “’501 patent”), 6,315,720 (the “’720 patent”), 6,555,554 (the “’554 patent”), 6,561,976 (the “’976 patent”), 6,561,977 (the “’977 patent”), 6,755,784 (the “’784 patent”), 7,119,106 (the “’106 patent”) and 7,465,800 (the “800 patent”) are invalid, unenforceable and/or not infringed.  Natco’s Notice Letter was sent in connection with its filing of an ANDA seeking permission from the FDA to market a generic version of 25mg, 15mg, 10mg and 5mg REVLIMID® capsules.
	On October 8, 2010, we filed an infringement action in the United States District Court of New Jersey against Natco in response to the Notice Letter with respect to the ’517 patent, the ’501 patent, United States Patent No. 6,281,230 (the “’230 patent”), the ’720 patent, the ’554 patent, the ’976 patent, the ’977 patent, the ’784 patent, the ’106 patent and the ’800 patent.
	Natco responded to our infringement action on November 18, 2010, with its Answer, Affirmative Defenses and Counterclaims.  Natco has alleged (through Affirmative Defenses and Counterclaims) that the patents are invalid, unenforceable and/or not infringed by Natco’s proposed generic products.  After filing the infringement action, we learned the identity of Natco’s U.S. partner, Arrow International Limited (“Arrow”) and filed an amended complaint on January 7, 2011, adding Arrow as a defendant.  On March 25, 2011, we filed a second amended complaint naming Natco, Arrow and Watson Laboratories, Inc. (“Watson”, a wholly-owned subsidiary of Actavis, Inc. (formerly known as Watson Pharmaceuticals, Inc.), which is Arrow’s parent) as defendants.  Those three entities remain the current defendants in that action.
	On June 12, 2012, we received a Second Notice Letter from Natco, notifying us of Natco’s submission in its ANDA of new, additional Paragraph IV certifications against the ’517 patent, the ’230 patent and United States Patent Nos. 7,189,740 (the “’740 patent”), 7,855,217 (the “’217 patent”) and 7,968,569 (the “’569 patent”).  On July 20, 2012, we filed a new infringement action in the United States District Court of New Jersey against Natco, Arrow and Watson in response to the Second Notice Letter with respect to the ’517 patent, the ’230 patent, the ’740 patent and the ’569 patent, as well as two non-Orange Book listed patents, United States Patent Nos. 7,977,357 (the “’357 patent”) and 8,193,219 (the “’219 patent”). That action was consolidated with the original action. Natco filed its Answer and Counterclaims on September 28, 2012. Natco’s counterclaims in the second action are similar to its counterclaims in the first action. In the second action, Natco added counterclaims against United States Patent No. 8,204,763 (the “’763 patent”), which we have not asserted against Natco.  We moved to dismiss those counterclaims related to the ’763 patent for lack of subject matter jurisdiction and Natco withdrew its counterclaims after the Court ordered jurisdictional discovery.
	On March 14, 2013, we received a Third Notice Letter from Natco notifying us of Natco’s submission in its ANDA of new, additional Paragraph IV certifications against United States Patent Nos. 8,288,415 (the “’415 patent”) and 8,315,886 (the “’886” patent).  On March 22, 2013, we filed a Third Amended Complaint in the original action in the United States District Court of New Jersey against Natco, Arrow and Watson in response to the Third Notice Letter regarding the ‘415 and ‘886 patent.  Natco filed its Answer and Counterclaims on April 8, 2013.  Natco’s counterclaims in response to the Third Amended Complaint are similar to its counterclaims in the two previous actions.
	On April 16, 2013, we filed a Fourth Amended Complaint in the original action, in the United States District Court of New Jersey, which asserts another recently issued patent, United States Patent No. 8,404,717, against Natco, Arrow and Watson. Natco filed its Answer and Counterclaims on May 2, 2013. Natco's counterclaims in response to the Fourth Amended Complaint are similar to its counterclaims in the three previous actions. On May 6, 2013, we filed a Fifth Amended Complaint in the original action in the United States District Court of New Jersey, which asserts another recently issued patent, United States Patent No. 8,431,598, against Natco, Arrow and Watson.  Natco filed its Answer and Counterclaims on May 23, 2013.  Natco's counterclaims in response to the Fifth Amended Complaint are similar to its counterclaims in the four previous actions.
	A revised Scheduling Order was entered by the Court on May 7, 2013, setting the close of fact discovery for January 20, 2014. Claim construction is currently expected to be fully briefed by the end of December 2013. Dates for a claim construction hearing and trial have yet to be set.
	We believe that Natco’s defenses and counterclaims are unlikely to be sustained and we intend to vigorously defend our patent rights.  We believe it unlikely that (i) Natco will prevail on each and every patent and patent claim subject to the lawsuits and (ii) all of the patent claims will be deemed to be invalid, unenforceable and/or not infringed.  Accordingly, the ultimate outcome is not expected to have a material adverse effect on our financial condition or results of operations.
	However, if Natco is successful in challenging our patents and the FDA were to approve Natco’s ANDA with a comprehensive education and risk management program for a generic version of lenalidomide and a generic product were to be introduced, sales of REVLIMID® could be significantly reduced in the United States, which would have a material adverse effect on our results of operations, cash flows and financial condition.
	ABRAXANE®:  On December 14, 2011, Cephalon, Inc. and Acusphere, Inc. filed a complaint against us in the United States District Court for the District of Massachusetts, alleging, among other things, that the making, using, selling, offering to sell and importing  of ABRAXANE® brand drug infringes claims of United States Patent No. RE40,493. Plaintiffs are seeking damages and injunctive relief. Pursuant to the agreement of the parties, discovery will proceed only with respect to claim construction.  A hearing regarding the disputed claims of the patent occurred on August 29, 2013.  The court has not yet ruled on the disputed claims.  After the Court’s ruling on the disputed claims, discovery on all other issues will proceed.  We intend to vigorously defend against this infringement suit.  If the suit against us is successful, we may have to pay damages, ongoing royalties and may have to license rights from plaintiffs.  However, we believe that (a) it is unlikely that the plaintiffs in this matter will prevail and (b) the ultimate outcome will not have a material adverse effect on our financial condition or results of operations.
	VIDAZA®:  On September 28, 2012, we were named as a defendant in a complaint filed by Ivax LLC (formerly Ivax Corporation) (“Ivax”) in the United States District Court for the Southern District of Florida.  Ivax LLC alleges that we have infringed the claims of United States Patent No. 7,759,481 (the “‘481 patent”) by making, using and selling VIDAZA® brand drug in the United States.  On October 19, 2012, we filed an answer to this complaint and filed a counterclaim asserting that the ‘481 patent was invalid and unenforceable.  We filed a motion for judgment on the pleadings on November 15, 2012, to which Ivax LLC filed an opposition on December 7, 2012.  On March 7, 2013 the Court granted in part and denied in part our motion for judgment on the pleadings.  Specifically, the Court dismissed Ivax’s complaint without prejudice and ordered Ivax to (i) either file an amended complaint with all necessary factual allegations or (ii) file dismissal papers by March 15, 2013.  The Court denied our motion for judgment on the pleadings with respect to our counterclaim.
	On March 13, 2013, Ivax filed an amended complaint. On March 28, 2013 we filed an answer and invalidity counterclaim in response to Ivax’s amended complaint.  A trial date of July 14, 2014 is currently scheduled.  At Celgene's request, the Court has ordered that discovery shall be phased to focus on a threshold issue relating to the potential invalidity of the patent.  Pursuant to the Court's Order, on or before September 16, 2013, Ivax was required to complete its evaluation of the discovery from the initial phase and report to the Court whether it will continue with the case.  On September 16, 2013, Ivax filed a case status report with the Court stating that the parties had reached an agreement in principle on a resolution of this case.  In the interim, all discovery as to other issues is stayed.  If final agreement is not reached, the case will continue, in which event we intend to vigorously defend against this infringement suit.  If the suit against us is successful, we may have to pay damages and/or ongoing royalties to the plaintiff.  However, we believe (a) that it is unlikely that the plaintiff in this matter will prevail and (b) that the ultimate outcome will not have a material adverse effect on our financial condition or results of operations.
	THALOMID® and REVLIMID®: On October 2, 2013, Andrulis Pharmaceuticals Corporation (Andrulis) filed a lawsuit against us in the United States District Court for the District of Delaware claiming infringement of U.S. Patent No. 6,140,346 (“the ‘346 patent”) entitled “Treatment of Cancer with Thalidomide Alone or in Combination with Other Anti-Cancer Agents.”  Andrulis alleges that we directly infringed, induced infringement of and/or contributed to infringement of one or more claims of the ‘346 patent, by making, using and selling THALOMID® and REVLIMID® in combination with an alkylating agent, e.g., melphalan, to treat cancers.  Andrulis is seeking an unspecified amount of damages, attorneys’ fees and injunctive relief with respect to the claimed combination. We disagree with Andrulis’ allegations and intend to vigorously defend against this infringement suit. We are required to respond to the complaint on or before November 25, 2013. We believe that the ultimate outcome of this lawsuit will not have a material adverse effect on our financial condition or results of operations.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]
Investments in Other Entities	Investments in Other Entities: Investments in equity securities of companies that become publicly traded are accounted for as available-for-sale marketable securities prospectively from the date of such companies' initial public offering.
New Accounting Pronouncements	New Accounting Pronouncements: In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update “Comprehensive Income (Topic 220):  Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” (ASU 2013-2).  ASU 2013-2 requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under U.S. generally accepted accounting principles (GAAP) to be reclassified in its entirety to net income.  The amendments require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component.  An entity shall provide this information together, in one location, either on the face of the statement where net income is presented or as a separate disclosure in the notes to the financial statements.  The amendments are effective prospectively for reporting periods beginning after December 15, 2012.  The adoption of ASU 2013-2 did not have a material impact on our financial position or results of operations.
	In July 2013, the FASB issued Accounting Standards Update "Derivatives and Hedging (Topic 815): Inclusion of the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a Benchmark Interest Rate for Hedge Accounting Purposes" (ASU 2013-10). ASU 2013-10 permits the use of the Fed Funds Effective Swap Rate (also referred to as the Overnight Index Swap Rate), in addition to the U.S. government rate (UST) and London Interbank Offered Rate (LIBOR), as a U.S. benchmark interest rate for hedge accounting purposes. This update is effective prospectively for qualifying new or re-designated hedging relationships entered into on or after July 17, 2013. The adoption of ASU 2013-10 did not have a material impact on our financial position or results of operations.
	In July 2013, the FASB issued Accounting Standards Update "Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists" (ASU 2013-11). ASU 2013-11 requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss (NOL) carryforward, or similar tax loss or tax credit carryforward, rather than as a liability when (1) the uncertain tax position would reduce the NOL or other carryforward under the tax law of the applicable jurisdiction and (2) the entity intends to use the deferred tax asset for that purpose. ASU 2013-11 is effective prospectively for fiscal years and interim periods within those years, beginning after December 15, 2013 for public entities. Early adoption and retrospective application are permitted. We do not expect the adoption of ASU 2013-11 to have a material impact on our financial position or results of operations.

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]
Schedule of earnings per share
		Three-Month Periods Ended September 30,				Nine-Month Periods Ended September 30,
	(Amounts in millions, except per share)	2013		2012		2013		2012
	Net income	$	372.5	$	424.2	$	1,235.50	$	1,193.10
	Weighted-average shares:
	Basic	412.3		427.2		414.7		434.1
	Effect of dilutive securities:
	Options, restricted stock units, warrants and other incentives	16.5		9.1		15.8		9.3
	Diluted	428.8		436.3		430.5		443.4
	Net income per share:
	Basic	$	0.9	$	0.99	$	2.98	$	2.75
	Diluted	$	0.87	$	0.97	$	2.87	$	2.69

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Summary of other comprehensive income (loss)	The accumulated balances related to each component of other comprehensive income (loss), net of tax, are summarized as follows:
		Pension				Net Unrealized			Net Unrealized				Foreign				Total
		Liability				Gains (Losses) From			Gains (Losses)				Currency				Accumulated
						Marketable Securities			From Hedges				Translation				Other
													Adjustment				Comprehensive
																	Income (Loss)
	Balance December 31, 2012	$	(10.1	)		$	4.2		$	(16.1	)		$	(27.7	)		$	(49.7	)
	Other comprehensive income (loss) before reclassifications	—				137.6			(3.2		)		22				156.4
	Amounts reclassified from accumulated other comprehensive income	—				4.4			(11.6		)		—				(7.2		)
	Net current-period other comprehensive income (loss)	—				142			(14.8		)		22				149.2
	Balance September 30, 2013	$	(10.1	)		$	146.2		$	(30.9	)		$	(5.7	)		$	99.5
	Balance December 31, 2011	$	(5.4	)		$	1.8		$	8.7			$	(67.4	)		$	(62.3	)
	Other comprehensive income before reclassifications	—				3.3			21.1				19.9				44.3
	Amounts reclassified from accumulated other comprehensive income	—				0.1			(59.9		)		—				(59.8		)
	Net current-period other comprehensive income (loss)	—				3.4			(38.8		)		19.9				(15.5		)
	Balance September 30, 2012	$	(5.4	)		$	5.2		$	(30.1	)		$	(47.5	)		$	(77.8	)
Schedule of gains (losses) reclassified out of accumulated other comprehensive income
					Gains (Losses) Reclassified Out of Accumulated
					Other Comprehensive Income
	Accumulated Other Comprehensive		Affected Line Item in the Consolidated Statements of		Three-Month Periods Ended September 30,							Nine-Month Periods Ended September 30,
	Income Components		Income		2013			2012				2013				2012
	Gains (losses) from cash-flow hedges:
	Foreign exchange contracts		Net product sales		$	12		$	24.8			$	7.6			$	62.8
	Treasury rate lock agreements		Interest (expense)		(0.9		)	(0.5		)		(2.5		)		(0.5		)
			Income tax benefit (expense)		0.3			0.6				6.5				(2.4		)
	Gains (losses) from available-for-sale marketable securities:
	Realized income (loss) on sales of marketable securities		Interest and investment income, net		(3.0		)	(0.4		)		(6.2		)		(0.1		)
			Income tax benefit		0.8			—				1.8				—
	Total reclassification, net of tax				$	9.2		$	24.5			$	7.2			$	59.8

Financial_Instruments_and_Fair1

Financial Instruments and Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]
Assets and liabilities measured at fair value on recurring basis
		Balance at			Quoted Price in			Significant			Significant
		September 30, 2013			Active Markets for			Other Observable			Unobservable
					Identical Assets			Inputs			Inputs
					(Level 1)			(Level 2)			(Level 3)
	Assets:
	Available-for-sale securities	$	3,424.30		$	422.3		$	3,002.00		$	—
	Cash equivalents	52			—			52			—
	Total assets	$	3,476.30		$	422.3		$	3,054.00		$	—
	Liabilities:
	Forward currency contracts	$	(8.9	)	$	—		$	(8.9	)	$	—
	Contingent value rights	(347.9		)	(347.9		)	—			—
	Written currency options	(0.3		)	—			(0.3		)	—
	Interest rate swaps	(31.5		)	—			(31.5		)	—
	Other acquisition related contingent consideration	(207.0		)	—			—			(207.0		)
	Total liabilities	$	(595.6	)	$	(347.9	)	$	(40.7	)	$	(207.0	)
		Balance at			Quoted Price in			Significant			Significant
		December 31, 2012			Active Markets for			Other Observable			Unobservable
					Identical Assets			Inputs			Inputs
					(Level 1)			(Level 2)			(Level 3)
	Assets:
	Available-for-sale securities	$	1,809.90		$	0.3		$	1,809.60		$	—
	Cash equivalents	27			—			27			—
	Interest rate swaps	1.7			—			1.7			—
	Forward currency contracts	17.8			—			17.8			—
	Purchased currency options	2.7			—			2.7			—
	Total assets	$	1,859.10		$	0.3		$	1,858.80		$	—
	Liabilities:
	Contingent value rights	$	(277.4	)	$	(277.4	)	$	—		$	—
	Written currency options	(5.1		)	—			(5.1		)	—
	Other acquisition related contingent consideration	(198.1		)	—			—			(198.1		)
	Total liabilities	$	(480.6	)	$	(277.4	)	$	(5.1	)	$	(198.1	)
Roll-forward of fair value of Level 3 instruments (significant unobservable inputs), liabilities
		Nine-Month Periods Ended September 30,
		2013			2012
	Liabilities:
	Balance at beginning of period	$	(198.1	)	$	(76.9	)
	Amounts acquired or issued	—			(171.7		)
	Net change in fair value	(8.9		)	35.6
	Settlements	—			—
	Transfers in and/or out of Level 3	—			—
	Balance at end of period	$	(207.0	)	$	(213.0	)

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Activities (Tables)

9 Months Ended

Sep. 30, 2013

Derivative Instruments and Hedging Activities

Schedule of fair value and balance sheet location of derivative instruments

September 30, 2013

Asset Derivatives

Liability Derivatives

Instrument

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments:

Other current assets

$

62.6

Other current assets

$

24.7

Foreign exchange contracts*

Other current liabilities

35.2

Other current liabilities

70.5

Other non-current assets

31.4

Other non-current assets

19.5

Other non-current liabilities

0.9

Other non-current liabilities

17.4

Other current assets

11.4

Other current assets

—

Interest rate swap agreements

Other non-current assets

0.3

Other non-current assets

—

Other non-current liabilities

—

Other non-current liabilities

44.8

Derivatives not designated as hedging instruments:

Foreign exchange contracts*

Other current assets

20

Other current assets

6.2

Other current liabilities

5.5

Other current liabilities

27.5

Other non-current assets

1.1

Other non-current assets

—

Interest rate swap agreements

Other non-current assets

1.6

Other non-current assets

—

Total

$

170

$

210.6

December 31, 2012

Asset Derivatives

Liability Derivatives

Instrument

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments:

Other current assets

$

35.2

Other current assets

$

12.7

Foreign exchange contracts*

Other current liabilities

9.1

Other current liabilities

31.4

Other non-current assets

30.5

Other non-current assets

13.8

Other current assets

0.1

Other current assets

—

Interest rate swap agreements

Other non-current assets

0.1

Other non-current assets

0.2

Other non-current liabilities

—

Other non-current liabilities

0.6

Derivatives not designated as hedging instruments:

Foreign exchange contracts*

Other current assets

45.8

Other current assets

36.3

Other current liabilities

10.4

Other current liabilities

21.4

Interest rate swap agreements

Other current assets

0.6

Other current assets

—

Other non-current assets

1.7

Other non-current assets

—

Total

$

133.5

$

116.4

* Derivative instruments in this category are subject to master netting arrangements and are presented on a net basis in the Consolidated Balance Sheets in accordance with ASC 210-20.

Cash flow hedges

Derivative Instruments and Hedging Activities

Schedule of effect of derivative instruments designated as hedging instruments on Consolidated Statements of Income

Three-Month Period Ended September 30, 2013

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Recognized in OCI

Reclassified from

Reclassified from

Recognized in

Recognized in

on Derivative (1)

Accumulated OCI

Accumulated OCI

Income on

Income on

into Income

into Income

Derivative

Derivative

Instrument

(Effective Portion)

(Effective Portion)

(Effective Portion)

(Ineffective Portion

(Ineffective Portion

and Amount Excluded

and Amount Excluded

From Effectiveness

From Effectiveness

Testing)

Testing)

Foreign exchange contracts

$

(89.8

)

Net product sales

$

11.9

Other income, net

$

5.1

-2

Treasury rate lock agreements

$

—

Interest expense

$

(0.9

)

(1) Net losses of $1.9 million are expected to be reclassified from Accumulated OCI into income in the next 12 months.

(2) The amount of net gains recognized in income represents $5.3 million of gains related to amounts excluded from the assessment of hedge effectiveness and $0.2 million of losses related to the ineffective portion of the hedging relationships.

Three-Month Period Ended September 30, 2012

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Recognized in OCI

Reclassified from

Reclassified from

Recognized in

Recognized in

on Derivative

Accumulated OCI

Accumulated OCI

Income on

Income on

into Income

into Income

Derivative

Derivative

Instrument

(Effective Portion)

(Effective Portion)

(Effective Portion)

(Ineffective Portion

(Ineffective Portion

and Amount Excluded

and Amount Excluded

From Effectiveness

From Effectiveness

Testing)

Testing)

Foreign exchange contracts

$

(24.5

)

Net product sales

$

24.8

Other income, net

$

(1.7

)

-1

Treasury rate lock agreements

$

(3.5

)

Interest expense

$

(0.5

)

(1) The amount of net losses recognized in income represents $2.2 million in losses related to the ineffective portion of the hedging relationships and $0.5 million of gains related to amounts excluded from the assessment of hedge effectiveness.

Nine-Month Period Ended September 30, 2013

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Recognized in OCI

Reclassified from

Reclassified from

Recognized in

Recognized in

on Derivative

Accumulated OCI

Accumulated OCI

Income on

Income on

into Income

into Income

Derivative

Derivative

Instrument

(Effective Portion)

(Effective Portion)

(Effective Portion)

(Ineffective Portion

(Ineffective Portion

and Amount Excluded

and Amount Excluded

From Effectiveness

From Effectiveness

Testing)

Testing)

Foreign exchange contracts

$

(3.2

)

Net product sales

$

7.6

Other income, net

$

9

(1

)

Treasury rate lock agreements

$

—

Interest expense

$

(2.5

)

(1) The amount of net gains recognized in income represents $1.7 million in gains related to the ineffective portion of the hedging relationships and $7.3 million of gains related to amounts excluded from the assessment of hedge effectiveness.

Nine-Month Period Ended September 30, 2012

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Gain/(Loss)

Recognized in OCI

Reclassified from

Reclassified from

Recognized in

Recognized in

on Derivative

Accumulated OCI

Accumulated OCI

Income on

Income on

into Income

into Income

Derivative

Derivative

Instrument

(Effective Portion)

(Effective Portion)

(Effective Portion)

(Ineffective Portion

(Ineffective Portion

and Amount Excluded

and Amount Excluded

From Effectiveness

From Effectiveness

Testing)

Testing)

Foreign exchange contracts

$

43.3

Net product sales

$

62.8

Other income, net

$

(3.4

)

-1

Treasury rate lock agreements

$

(35.3

)

Interest expense

$

(0.5

)

(1) The amount of net losses recognized in income represents $7.5 million in losses related to the ineffective portion of the hedging relationships and $4.1 million of gains related to amounts excluded from the assessment of hedge effectiveness.

Fair value hedges

Derivative Instruments and Hedging Activities

Schedule of effect of derivative instruments designated as hedging instruments on Consolidated Statements of Income

Amount of Gain (Loss) Recognized in

Income on Derivative

Location of Gain (Loss) Recognized in Income

Three-Month Periods Ended September 30,

Nine-Month Periods Ended September 30,

Instrument

on Derivative

2013

2012

2013

2012

Interest rate swap agreements

Interest expense

$

9.8

$

2

$

21.8

$

5.6

Amount of Gain (Loss) Recognized in

Income on Derivative

Location of Gain (Loss) Recognized in Income

Three-Month Periods Ended September 30,

Nine-Month Periods Ended September 30,

Instrument

on Derivative

2013

2012

2013

2012

Foreign exchange contracts

Other income, net

$

(27.0

)

$

(11.5

)

$

(42.2

)

$

4.5

Treasury rate lock agreements

Other income, net

$

—

$

—

$

—

$

3.7

Foreign currency forward contracts

Derivative Instruments and Hedging Activities

Schedule of notional amount of derivative contracts

Notional Amount

Foreign Currency

September 30, 2013

December 31, 2012

Australian Dollar

$

53.7

$

5.1

British Pound

313.8

77.9

Canadian Dollar

84.7

134.4

Euro

2,425.30

969.3

Japanese Yen

703.2

236.2

Total

$

3,580.70

$

1,422.90

Foreign currency option contracts

Derivative Instruments and Hedging Activities

Schedule of notional amount of derivative contracts

Notional Amount*

Foreign Currency Option

September 30, 2013

December 31, 2012

Designated as hedging activity:

Purchased Put

$

24.3

$

228.8

Written Call

$

25.4

$

235.9

Not designated as hedging activity:

Purchased Put

$

22.7

$

160.5

Written Put

$

(22.7

)

$

(216.0

)

* U.S. Dollar notional amounts are calculated as the hedged local currency amount multiplied times the strike value of the foreign currency option.  The local currency notional amounts of our purchased put and written call that are designated as hedging activity are equal to each other.

Interest rate swap contracts

Derivative Instruments and Hedging Activities

Schedule of notional amount of derivative contracts

Notional Amount

September 30, 2013

December 31, 2012

Interest rate swap contracts entered into as fair value hedges of the following fixed-rate senior notes:

2.450% senior notes due 2015

$

300

$

—

1.900% senior notes due 2017

300

100

3.950% senior notes due 2020

500

—

3.250% senior notes due 2022

850

200

4.000% senior notes due 2023

50

—

Total

$

2,000.00

$

300

Cash_Cash_Equivalents_and_Mark1

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Tables)	9 Months Ended
	Sep. 30, 2013
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Schedule of available-for-sale securities by major security type and class
	September 30, 2013	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss			Estimated Fair Value
	U.S. Treasury securities	$	1,017.20	$	0.7	$	—		$	1,017.90
	U.S. government-sponsored agency securities	400.1		0.2		(0.9		)	399.4
	U.S. government-sponsored agency MBS	587.1		0.5		(7.9		)	579.7
	Non-U.S. government, agency and Supranational securities	74.2		—		(0.1		)	74.1
	Corporate debt - global	701.8		0.9		(1.2		)	701.5
	Asset backed securities	229.6		0.1		(0.3		)	229.4
	Marketable equity securities	190.7		231.6		—			422.3
	Total available-for-sale marketable securities	$	3,200.70	$	234	$	(10.4	)	$	3,424.30
	December 31, 2012	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss			Estimated Fair Value
	U.S. Treasury securities	$	902	$	0.5	$	—		$	902.5
	U.S. government-sponsored agency securities	303.5		0.3		—			303.8
	U.S. government-sponsored agency MBS	387.2		1.6		(1.8		)	387
	Non-U.S. government, agency and Supranational securities	7.1		—		—			7.1
	Corporate debt - global	208.5		0.9		(0.2		)	209.2
	Marketable equity securities	0.4		—		(0.1		)	0.3
	Total available-for-sale marketable securities	$	1,808.70	$	3.3	$	(2.1	)	$	1,809.90
Schedule of duration periods of available-for-sale debt securities
		Amortized		Fair
		Cost		Value
	Duration of one year or less	$	1,370.40	$	1,369.30
	Duration of one through three years	1,419.00		1,415.70
	Duration of three through five years	203.7		200.4
	Duration of over five years	16.9		16.6
	Total	$	3,010.00	$	3,002.00

Inventory_Tables

Inventory (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]
Summary of inventories by major category	A summary of inventories by major category at September 30, 2013 and December 31, 2012 follows:
		September 30, 2013		December 31, 2012
	Raw materials	$	125.7	$	79.2
	Work in process	96.4		86.5
	Finished goods	91.2		93.8
	Total	$	313.3	$	259.5

Intangible_Assets_and_Goodwill1

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets by category	The following summary of intangible assets by category includes intangibles currently being amortized and intangibles not yet subject to amortization:
	September 30, 2013		Gross Carrying Value		Accumulated Amortization			Intangible Assets, Net		Weighted Average Life (Years)
	Amortizable intangible assets:
	Acquired developed product rights		$	3,405.90	$	(973.4	)	$	2,432.50	13
	Technology		333.7		(75.5		)	258.2		7
	Licenses		66.2		(12.9		)	53.3		16.5
	Other		45		(18.7		)	26.3		8.3
			3,850.80		(1,080.5		)	2,770.30		12.5
	Non-amortized intangible assets:
	Acquired IPR&D product rights		137.9		—			137.9
	Total intangible assets		$	3,988.70	$	(1,080.5	)	$	2,908.20
	December 31, 2012		Gross Carrying Value		Accumulated Amortization			Intangible Assets, Net		Weighted Average Life (Years)
	Amortizable intangible assets:
	Acquired developed product rights		$	3,400.40	$	(814.5	)	$	2,585.90	13
	Technology		333.3		(39.8		)	293.5		7
	Licenses		64.3		(10.0		)	54.3		16.8
	Other		43.4		(14.6		)	28.8		8.5
			3,841.40		(878.9		)	2,962.50		12.5
	Non-amortized intangible assets:
	Acquired IPR&D product rights		137.9		—			137.9
	Total intangible assets		$	3,979.30	$	(878.9	)	$	3,100.40
Schedule of changes in carrying value of goodwill	The change in carrying value of goodwill is summarized as follows:
	Balance at December 31, 2012	$	2,042.80
	Tax benefit on the exercise of Pharmion converted stock options	(0.7		)
	Balance at September 30, 2013	$	2,042.10

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]
Carrying values of the senior notes	Summarized below are the carrying values of our senior notes at September 30, 2013 and December 31, 2012:
		September 30, 2013		December 31, 2012
	2.450% senior notes due 2015	$	515.7	$	520.1
	1.900% senior notes due 2017	500.8		500.6
	2.300% senior notes due 2018	400.1		—
	3.950% senior notes due 2020	492.4		499
	3.250% senior notes due 2022	975		1,002.10
	4.000% senior notes due 2023	698.1		—
	5.700% senior notes due 2040	249.6		249.5
	5.250% senior notes due 2043	396.6		—
	Total long-term debt	$	4,228.30	$	2,771.30

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Components of share-based compensation expense	The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Income for the three- and nine-month periods ended September 30, 2013 and 2012:
		Three-Month Periods Ended							Nine-Month Periods Ended
		September 30,							September 30,
		2013			2012				2013		2012
	Cost of goods sold (excluding amortization of acquired intangible assets)	$	6.1		$	3.3			$	12.6	$	9.2
	Research and development	41.7			27.2				100.5		75.8
	Selling, general and administrative	44.2			32.1				114.3		86
	Total share-based compensation expense	92			62.6				227.4		171
	Tax benefit related to share-based compensation expense	29.9			17				66.1		45.7
	Reduction in income	$	62.1		$	45.6			$	161.3	$	125.3
Summary of activity for stock options, RSUs and PSUs	The following table summarizes the activity for stock options, RSUs and PSUs for the nine-month period ended September 30, 2013 (in thousands):
		Stock		Restricted			Performance-
		Options		Stock			Based Restricted
				Units			Stock
							Units
	Outstanding at December 31, 2012	42,592		4,463			26
	Changes during the Year:
	Granted	6,639		1,517			45
	Exercised / Released	(9,951	)	(832	)		(6	)
	Forfeited	(863	)	(173	)		(8	)
	Expired	(36	)	N/A			N/A
	Outstanding at September 30, 2013	38,381		4,975			57
Schedule of total compensation cost related to nonvested awards not yet recognized and weighted-average periods over which awards are expected to be recognized	Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2013 were as follows (dollars in millions):
		Stock			Restricted				Performance-
		Options			Stock				Based Restricted
					Units				Stock Units
	Unrecognized compensation cost	$	369.7		$	243.6			$	4.4
	Expected weighted-average period in years of compensation cost to be recognized	2.2			1.6				1.8

Nature_of_Business_and_Basis_o1

Nature of Business and Basis of Presentation Nature of Business and Basis of Presentation (Details)	9 Months Ended
	Sep. 30, 2013
	Systemic_Therapy
Nature of Business and Basis of Presentation [Abstract]
Number of Prior Systemic Therapies	2
Period for Demonstration of Disease Progression from Completion of Last Therapy	60 days
Maximum Equity Ownership Percentage, Investments	50.00%

Acquisitions_Details

Acquisitions (Details) (USD $)	9 Months Ended		0 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Mar. 07, 2012	Mar. 07, 2012	Sep. 30, 2013	Mar. 07, 2012	Oct. 04, 2013	Dec. 31, 2012	Sep. 30, 2013
			Avila Therapeutics, Inc.	Avila Therapeutics, Inc.	Avila Therapeutics, Inc.	Avila Therapeutics, Inc.	Abraxis BioScience,Inc. [Member] [Member]	Abraxis BioScience,Inc. [Member] [Member]	Abraxis Bio Science, Inc. [Member]
				Minimum	Maximum	Maximum
Business Acquisition [Line Items]
Payments for acquisition of business, net of cash acquired	$0	$352,200,000	$352,200,000
Potential milestone payment				0	595,000,000	595,000,000	300,000,000
Fair value of contingent consideration								$277,400,000	$347,900,000

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	1 Months Ended		3 Months Ended		9 Months Ended		54 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Jun. 30, 2013	Feb. 28, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Earnings Per Share [Abstract]
Net income			$372,500,000	$424,200,000	$1,235,500,000	$1,193,100,000
Weighted average shares:
Basic (in shares)			412.3	427.2	414.7	434.1
Effect of dilutive securities:
Options, restricted stock units, warrants and other incentives			16.5	9.1	15.8	9.3
Diluted (in shares)			428.8	436.3	430.5	443.4
Net income per share attributable to Celgene:
Basic (in dollars per share)			$0.90	$0.99	$2.98	$2.75
Diluted (in dollars per share)			$0.87	$0.97	$2.87	$2.69
Anti-dilutive securities
Antidilutive securities excluded from computation of earnings per share (in shares)			4.1	11.6	5.1	11.5
Approved common share repurchase amount	$3,000,000,000	$600,000,000			$2,790,000,000		$9,500,000,000
Shares repurchased under share repurchase program					5.2
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price					$114.30
Common stock repurchased under the program during the period (in shares)			1.5		17.8

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at the beginning of the period			($49.70)	($62.30)
Other comprehensive income before reclassifications			156.4	44.3
Amounts reclassified from accumulated other comprehensive income			-7.2	-59.8
Total other comprehensive income (loss)	23.7	-44.9	149.2	-15.5
Balance at the end of the period	99.5	-77.8	99.5	-77.8
Pension Liability
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at the beginning of the period			-10.1	-5.4
Other comprehensive income before reclassifications			0	0
Amounts reclassified from accumulated other comprehensive income			0	0
Total other comprehensive income (loss)			0	0
Balance at the end of the period	-10.1	-5.4	-10.1	-5.4
Net Unrealized Gains (Losses) From Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at the beginning of the period			4.2	1.8
Other comprehensive income before reclassifications			137.6	3.3
Amounts reclassified from accumulated other comprehensive income			4.4	0.1
Total other comprehensive income (loss)			142	3.4
Balance at the end of the period	146.2	5.2	146.2	5.2
Net Unrealized Gains (Losses) From Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at the beginning of the period			-16.1	8.7
Other comprehensive income before reclassifications			-3.2	21.1
Amounts reclassified from accumulated other comprehensive income			-11.6	-59.9
Total other comprehensive income (loss)			-14.8	-38.8
Balance at the end of the period	-30.9	-30.1	-30.9	-30.1
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at the beginning of the period			-27.7	-67.4
Other comprehensive income before reclassifications			22	19.9
Amounts reclassified from accumulated other comprehensive income			0	0
Total other comprehensive income (loss)			22	19.9
Balance at the end of the period	($5.70)	($47.50)	($5.70)	($47.50)

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income (Loss) (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Other Comprehensive Income (Loss)
Net product sales	$1,644	$1,388	$4,637.40	$3,970.10
Interest (expense)	-24	-17.9	-61.5	-40.7
Income tax benefit (expense)	-69.5	-52.3	-212.7	-198.1
Interest and investment income, net	5.3	2.8	14.6	9.6
Net income	372.5	424.2	1,235.50	1,193.10
Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income
Other Comprehensive Income (Loss)
Net income	9.2	24.5	7.2	59.8
Gains (losses) from cash-flow hedges: | Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income
Other Comprehensive Income (Loss)
Income tax benefit (expense)	0.3	0.6	6.5	-2.4
Gains (losses) from cash-flow hedges: | Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income | Foreign exchange contracts
Other Comprehensive Income (Loss)
Net product sales	12	24.8	7.6	62.8
Gains (losses) from cash-flow hedges: | Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income | Treasury rate lock agreements
Other Comprehensive Income (Loss)
Interest (expense)	-0.9	-0.5	-2.5	-0.5
Gains (losses) from available-for-sale marketable securities: | Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income
Other Comprehensive Income (Loss)
Income tax benefit (expense)	0.8	0	1.8	0
Interest and investment income, net	($3)	($0.40)	($6.20)	($0.10)

Financial_Instruments_and_Fair2

Financial Instruments and Fair Value Measurement (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Mar. 07, 2012
	Recurring basis	Recurring basis	Recurring basis	Recurring basis	Recurring basis	Recurring basis	Recurring basis	Recurring basis	Gloucester Pharmaceuticals, Inc.	Avila Therapeutics, Inc.	Avila Therapeutics, Inc.
	Fair Value	Fair Value	Quoted Price in Active Markets for Identical Assets (Level 1)	Quoted Price in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Significant Unobservable Inputs (Level 3)	Maximum	Maximum	Maximum
Fair Value of assets and liabilities
Potential milestone payment									$120,000,000	$595,000,000	$595,000,000
Assets:
Available-for-sale securities	3,424,300,000	1,809,900,000	422,300,000	300,000	3,002,000,000	1,809,600,000
Cash equivalents	52,000,000	27,000,000			52,000,000	27,000,000
Interest rate swaps		1,700,000				1,700,000
Forward currency contracts		17,800,000				17,800,000
Purchased currency options		2,700,000				2,700,000
Total assets	3,476,300,000	1,859,100,000	422,300,000	300,000	3,054,000,000	1,858,800,000
Liabilities:
Forward currency contracts	-8,900,000				-8,900,000
Contingent value rights	-347,900,000	-277,400,000	-347,900,000	-277,400,000
Written currency options	-300,000	-5,100,000			-300,000	-5,100,000
Interest rate swaps	-31,500,000				-31,500,000
Other acquisition related contingent consideration	-207,000,000	-198,100,000					-207,000,000	-198,100,000
Total liabilities	($595,600,000)	($480,600,000)	($347,900,000)	($277,400,000)	($40,700,000)	($5,100,000)	($207,000,000)	($198,100,000)

Financial_Instruments_and_Fair3

Financial Instruments and Fair Value Measurement (Details 2) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Fair Value Disclosures [Abstract]
Amount of transfer of assets out of Level 1 into Level 2	$0	$0
Amount of transfer of assets out of Level 2 into Level 1	0	0
Amount of transfer of liabilities out of Level 1 into Level 2	0	0
Amount of transfer of liabilities out of Level 2 into Level 1	0	0
Roll forward of fair value of Level 3 instruments (significant unobservable inputs), Liabilities:
Balance at beginning of period	-198,100,000	-76,900,000
Amounts acquired or issued	0	-171,700,000
Net change in fair value	-8,900,000	35,600,000
Settlements	0	0
Transfers in and/or out of Level 3	0	0
Balance at end of period	($207,000,000)	($213,000,000)

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Activities (Details) (USD $)

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Aug. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

In Millions, unless otherwise specified

2.450% senior notes due 2015

2.450% senior notes due 2015

1.900% senior notes due 2017

1.900% senior notes due 2017

3.950% senior notes due 2020

3.950% senior notes due 2020

3.250% senior notes due 2022

3.250% senior notes due 2022

4.000% senior notes due 2023

4.000% senior notes due 2023

4.000% senior notes due 2023

Foreign currency forward contracts

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Foreign currency forward contracts

Foreign currency forward contracts

Foreign currency forward contracts

Foreign currency forward contracts

Foreign currency forward contracts

Foreign currency forward contracts

Foreign currency forward contracts

Foreign currency forward contracts

Foreign currency forward contracts

Foreign currency forward contracts

Foreign currency forward contracts

Foreign currency forward contracts

Foreign currency option contracts

Foreign currency option contracts

Foreign currency option contracts

Foreign currency option contracts

Treasury rate locks

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Foreign currency forward contracts

Foreign currency forward contracts

Foreign currency option contracts

Foreign currency option contracts

Foreign currency option contracts

Foreign currency option contracts

Australian Dollar

Australian Dollar

British Pound

British Pound

Canadian Dollar

Canadian Dollar

Euro

Euro

Japanese Yen

Japanese Yen

Purchased Put

Purchased Put

Written Call

Written Call

Subsequent Event

Subsequent Event

Subsequent Event

2.450% senior notes due 2015

2.450% senior notes due 2015

1.900% senior notes due 2017

1.900% senior notes due 2017

3.950% senior notes due 2020

3.950% senior notes due 2020

3.250% senior notes due 2022

3.250% senior notes due 2022

4.000% senior notes due 2023

4.000% senior notes due 2023

Purchased Put

Purchased Put

Written put

Written put

5 year maturity

10 year maturity

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Derivative Instruments and Hedging Activities

Period to settlement dates of derivatives is within this period

3 years

36 months

36 months

Summary of Derivative Instruments

Notional amount

$3,580.70

$1,422.90

$53.70

$5.10

$313.80

$77.90

$84.70

$134.40

$2,425.30

$969.30

$703.20

$236.20

$24.30

[1]

$228.80

[1]

$25.40

[1]

$235.90

[1]

$2,000

$2,000

$300

$300

$0

$300

$100

$500

$0

$850

$200

$50

$0

$22.70

[1]

$160.50

[1]

($22.70)

[1]

($216)

[1]

Notional amount entered into during period

100

150

100

50

Derivative term

10 years

Aggregate notional amount of foreign currency forward non-designated hedging contracts

816.1

795.4

Derivative settlement losses

35.3

Interest rate (as a percent)

2.45%

2.45%

1.90%

1.90%

3.95%

3.95%

3.25%

3.25%

4.00%

4.00%

4.00%

Proceeds from settlement of interest rate swap contracts

$21.90

[1]

U.S. Dollar notional amounts are calculated as the hedged local currency amount multiplied times the strike value of the foreign currency option. The local currency notional amounts of our purchased put and written call that are designated as hedging activity are equal to each other.

Derivative_Instruments_and_Hed3

Derivative Instruments and Hedging Activities (Details 2) (USD $)	Sep. 30, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Fair value of derivative instruments
Asset Derivative	$170		$133.50
Liability Derivative	210.6		116.4
Designated as hedging instruments | Foreign exchange contracts | Other current assets
Fair value of derivative instruments
Asset Derivative	62.6	[1]	35.2	[1]
Liability Derivative	24.7	[1]	12.7	[1]
Designated as hedging instruments | Foreign exchange contracts | Other current liabilities
Fair value of derivative instruments
Asset Derivative	35.2	[1]
Asset Derivative			9.1	[1]
Liability Derivative	70.5	[1]	31.4	[1]
Designated as hedging instruments | Foreign exchange contracts | Other non-current assets
Fair value of derivative instruments
Asset Derivative	31.4	[1]	30.5	[1]
Liability Derivative	19.5	[1]	13.8	[1]
Designated as hedging instruments | Foreign exchange contracts | Other non-current liabilities
Fair value of derivative instruments
Asset Derivative	0.9	[1]
Liability Derivative	17.4	[1]
Designated as hedging instruments | Interest rate swap agreements | Other current assets
Fair value of derivative instruments
Asset Derivative	11.4		0.1
Designated as hedging instruments | Interest rate swap agreements | Other non-current assets
Fair value of derivative instruments
Asset Derivative	0.3		0.1
Liability Derivative	0		0.2
Designated as hedging instruments | Interest rate swap agreements | Other non-current liabilities
Fair value of derivative instruments
Liability Derivative	44.8		0.6
Not designated as hedging instruments | Foreign exchange contracts | Other current assets
Fair value of derivative instruments
Asset Derivative	20	[1]	45.8	[1]
Liability Derivative	6.2	[1]	36.3	[1]
Not designated as hedging instruments | Foreign exchange contracts | Other current liabilities
Fair value of derivative instruments
Asset Derivative	5.5	[1]	10.4	[1]
Liability Derivative	27.5	[1]	21.4	[1]
Not designated as hedging instruments | Foreign exchange contracts | Other non-current assets
Fair value of derivative instruments
Asset Derivative	1.1	[1]
Not designated as hedging instruments | Interest rate swap agreements | Other current assets
Fair value of derivative instruments
Asset Derivative			0.6
Not designated as hedging instruments | Interest rate swap agreements | Other non-current assets
Fair value of derivative instruments
Asset Derivative	$1.60	[1]	$1.70
[1]	Derivative instruments in this category are subject to master netting arrangements and are presented on a net basis in the Consolidated Balance Sheets in accordance with ASC 210-20.

Derivative_Instruments_and_Hed4

Derivative Instruments and Hedging Activities (Details 3) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

15 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Not designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Designated as hedging instruments

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Treasury rate locks

Treasury rate locks

Treasury rate locks

Treasury rate locks

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Cash flow hedges

Foreign exchange contracts

Fair value hedges

Fair value hedges

Fair value hedges

Fair value hedges

Other income, net

Other income, net

Other income, net

Other income, net

Other income, net

Other income, net

Other income, net

Other income, net

Other income, net

Other income, net

Other income, net

Other income, net

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Foreign exchange contracts

Treasury rate locks

Treasury rate locks

Treasury rate locks

Treasury rate locks

Treasury rate locks

Treasury rate locks

Treasury rate locks

Treasury rate locks

Other income, net

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Interest rate swap contracts

Net product sales

Net product sales

Net product sales

Net product sales

Other income, net

Other income, net

Other income, net

Other income, net

Interest expense

Interest expense

Interest expense

Interest expense

Interest expense

Interest expense

Interest expense

Interest expense

Effect of derivative instruments on Consolidated Statements of Income

Amount of Gain/(Loss) Recognized in OCI on Derivative (Effective Portion)

($27)

($11.50)

($42.20)

$4.50

$0

$0

$0

$3.70

($89.80)

[1]

($24.50)

($3.20)

[2]

$43.30

$0

[1]

($3.50)

$0

[2]

($35.30)

Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income (Effective Portion)

11.9

24.8

7.6

62.8

-0.9

-0.5

-2.5

-0.5

Amount of Gain/(Loss) Recognized in Income on Derivative

5.1

[3]

-1.7

[4]

9

[5]

-3.4

[6]

9.8

2

21.8

5.6

Gains (losses) expected to be reclassified from accumulated OCI into operations in the next 12 months

1.9

Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer

12 months

Gains related to amounts excluded from assessment of hedge effectiveness

7.3

4.1

0.5

5.3

Gains (losses) on ineffective portion

($0.20)

($1.70)

($7.50)

($2.20)

[1]

Net losses of $1.9 million are expected to be reclassified from Accumulated OCI into income in the next 12 months.

[2]

[3]

The amount of net gains recognized in income represents $5.3 million of gains related to amounts excluded from the assessment of hedge effectiveness and $0.2 million of losses related to the ineffective portion of the hedging relationships.

[4]

The amount of net losses recognized in income represents $2.2 million in losses related to the ineffective portion of the hedging relationships and $0.5 million of gains related to amounts excluded from the assessment of hedge effectiveness.

[5]

The amount of net gains recognized in income represents $1.7 million in gains related to the ineffective portion of the hedging relationships and $7.3 million of gains related to amounts excluded from the assessment of hedge effectiveness.

[6]

The amount of net losses recognized in income represents $7.5 million in losses related to the ineffective portion of the hedging relationships and $4.1 million of gains related to amounts excluded from the assessment of hedge effectiveness.

Cash_Cash_Equivalents_and_Mark2

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Cash and cash equivalents
Money market funds	$860.40	$1,160
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	3,200.70	1,808.70
Gross Unrealized Gain	234	3.3
Gross Unrealized Loss	-10.4	-2.1
Estimated Fair Value	3,424.30	1,809.90
U.S. Treasury securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,017.20	902
Gross Unrealized Gain	0.7	0.5
Gross Unrealized Loss	0
Estimated Fair Value	1,017.90	902.5
U.S. government-sponsored agency securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	400.1	303.5
Gross Unrealized Gain	0.2	0.3
Gross Unrealized Loss	-0.9
Estimated Fair Value	399.4	303.8
U.S. government-sponsored agency MBS
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	587.1	387.2
Gross Unrealized Gain	0.5	1.6
Gross Unrealized Loss	-7.9	-1.8
Estimated Fair Value	579.7	387
Non-U.S. government, agency and Supranational securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	74.2	7.1
Gross Unrealized Loss	-0.1
Estimated Fair Value	74.1	7.1
Corporate debt - global
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	701.8	208.5
Gross Unrealized Gain	0.9	0.9
Gross Unrealized Loss	-1.2	-0.2
Estimated Fair Value	701.5	209.2
Asset backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	229.6
Gross Unrealized Gain	0.1
Gross Unrealized Loss	-0.3
Estimated Fair Value	229.4
Marketable equity securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	190.7	0.4
Gross Unrealized Gain	231.6
Gross Unrealized Loss	0	-0.1
Estimated Fair Value	$422.30	$0.30

Cash_Cash_Equivalents_and_Mark3

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Details 2) (USD $)	Sep. 30, 2013
In Millions, unless otherwise specified
Amortized Cost
Duration of one year or less	$1,370.40
Duration of one through three years	1,419
Duration of three through five years	203.7
Duration of over five years	16.9
Total	3,010
Fair Value
Duration of one year or less	1,369.30
Duration of one through three years	1,415.70
Duration of three through five years	200.4
Duration of over five years	16.6
Total	$3,002

Inventory_Details

Inventory (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$125.70	$79.20
Work in process	96.4	86.5
Finished goods	91.2	93.8
Total	$313.30	$259.50

Intangible_Assets_and_Goodwill2

Intangible Assets and Goodwill (Details) (USD $)	3 Months Ended	9 Months Ended		12 Months Ended	15 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013
Intangible Assets By Category
Gross Carrying Value	$3,850,800,000	$3,850,800,000		$3,841,400,000	$3,850,800,000
Accumulated Amortization	-1,080,500,000	-1,080,500,000		-878,900,000	-1,080,500,000
Intangible Assets, Net	2,770,300,000	2,770,300,000		2,962,500,000	2,770,300,000
Weighted Average Life (Years)		12 years 6 months		12 years 6 months
Total intangible assets
Gross Carrying Value	3,988,700,000	3,988,700,000		3,979,300,000	3,988,700,000
Intangible Assets, Net	2,908,200,000	2,908,200,000		3,100,400,000	2,908,200,000
Increase in the gross carrying value of the intangible assets		9,400,000
Amortization expense	67,500,000	201,600,000	133,000,000		46,400,000
Summary of changes in carrying value of goodwill
Balance at December 31, 2012		2,042,800,000
Tax benefit on the exercise of Pharmion converted stock options		-700,000
Balance at September 30, 2013	2,042,100,000	2,042,100,000		2,042,800,000	2,042,100,000
Acquired developed product rights
Intangible Assets By Category
Gross Carrying Value	3,405,900,000	3,405,900,000		3,400,400,000	3,405,900,000
Accumulated Amortization	-973,400,000	-973,400,000		-814,500,000	-973,400,000
Intangible Assets, Net	2,432,500,000	2,432,500,000		2,585,900,000	2,432,500,000
Weighted Average Life (Years)		13 years		13 years
Total intangible assets
Acquired intangible assets	5,500,000	5,500,000			5,500,000
Technology
Intangible Assets By Category
Gross Carrying Value	333,700,000	333,700,000		333,300,000	333,700,000
Accumulated Amortization	-75,500,000	-75,500,000		-39,800,000	-75,500,000
Intangible Assets, Net	258,200,000	258,200,000		293,500,000	258,200,000
Weighted Average Life (Years)		7 years		7 years
Licenses
Intangible Assets By Category
Gross Carrying Value	66,200,000	66,200,000		64,300,000	66,200,000
Accumulated Amortization	-12,900,000	-12,900,000		-10,000,000	-12,900,000
Intangible Assets, Net	53,300,000	53,300,000		54,300,000	53,300,000
Weighted Average Life (Years)		16 years 6 months		16 years 9 months 18 days
Other
Intangible Assets By Category
Gross Carrying Value	45,000,000	45,000,000		43,400,000	45,000,000
Accumulated Amortization	-18,700,000	-18,700,000		-14,600,000	-18,700,000
Intangible Assets, Net	26,300,000	26,300,000		28,800,000	26,300,000
Weighted Average Life (Years)		8 years 3 months 13 days		8 years 6 months
Total intangible assets
Acquired intangible assets	3,900,000	3,900,000			3,900,000
Acquired IPR&D product rights
Non-amortized intangible assets:
Carrying Value	137,900,000	137,900,000		137,900,000	137,900,000
Minimum
Intangible Assets By Category
Weighted Average Life (Years)		1 year
Total intangible assets
Amortization		255,000,000
Maximum
Intangible Assets By Category
Weighted Average Life (Years)		17 years
Total intangible assets
Amortization		$270,000,000

Debt_Details

Debt (Details) (USD $)	1 Months Ended
	Aug. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
Carrying values of the entity's senior notes
Long-term debt		$4,228,300,000	$2,771,300,000
Senior notes, fair value		4,252,000,000
Interest rate swap contracts | Designated as hedging instruments
Carrying values of the entity's senior notes
Gains recorded as reduction of debt		33,800,000
2.450% senior notes due 2015
Carrying values of the entity's senior notes
Long-term debt		515,700,000	520,100,000
Interest rate (as a percent)		2.45%
2012 issued notes | Treasury rate locks
Carrying values of the entity's senior notes
Losses recorded to AOCI		31,400,000
1.900% senior notes due 2017
Carrying values of the entity's senior notes
Long-term debt		500,800,000	500,600,000
Interest rate (as a percent)		1.90%
3.250% senior notes due 2022
Carrying values of the entity's senior notes
Long-term debt		975,000,000	1,002,100,000
Interest rate (as a percent)		3.25%
2013 issued notes
Carrying values of the entity's senior notes
Debt Instrument, Increase, Additional Borrowings	1,500,000,000
Deferred Finance Costs, Noncurrent, Gross	12,500,000
Debt Instrument, Redemption Price as Percentage of Principal Amount	100.00%
Debt Instrument, Repurchase Price Due to Change in Control as Percentage of Principal Amount	101.00%
2.300% senior notes due 2018
Carrying values of the entity's senior notes
Long-term debt		400,100,000	0
Debt Instrument, Increase, Additional Borrowings	400,000,000
Interest rate (as a percent)	2.30%	2.30%
Issuance price as percentage of par value	99.79%
Debt Instrument, Interest Rate Increase	0.15
4.000% senior notes due 2023
Carrying values of the entity's senior notes
Long-term debt		698,100,000	0
Debt Instrument, Increase, Additional Borrowings	700,000,000
Interest rate (as a percent)	4.00%	4.00%
Issuance price as percentage of par value	99.45%
Debt Instrument, Interest Rate Increase	0.2
5.250% senior notes due 2043
Carrying values of the entity's senior notes
Long-term debt		396,600,000	0
Debt Instrument, Increase, Additional Borrowings	400,000,000
Interest rate (as a percent)	5.25%	5.25%
Issuance price as percentage of par value	99.15%
Debt Instrument, Interest Rate Increase	0.25
3.950% senior notes due 2020
Carrying values of the entity's senior notes
Long-term debt		492,400,000	499,000,000
Interest rate (as a percent)		3.95%
3.950% senior notes due 2020 | Interest rate swap contracts | Designated as hedging instruments
Carrying values of the entity's senior notes
Gains recorded as reduction of debt		14,700,000
5.700% senior notes due 2040
Carrying values of the entity's senior notes
Long-term debt		$249,600,000	$249,500,000
Interest rate (as a percent)		5.70%

Debt_Details_2

Debt (Details 2) (USD $)	1 Months Ended
	Apr. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
	Time_Per_Annum
increase in commercial paper maximum
Debt
Amount outstanding		$500,000,000
Commercial Paper
Debt
Effective interest rate (as a percent)		0.30%
Maximum
Debt
Amount outstanding		1,500,000,000
commercial paper carrying value
Debt
Amount outstanding		405,900,000	308,500,000
Senior Unsecured Credit Facility
Debt
Maximum borrowing capacity	1,000,000,000	1,500,000,000
Maximum number of credit facility increases	1
Maximum borrowing capacity, subject to certain conditions	1,750,000,000
Outstanding uncommitted facility		$0	$0

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	0 Months Ended	3 Months Ended	9 Months Ended		15 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 12, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012
Stock-Based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	104,981,641
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	9,000,000
Allocated share-based compensation expense		$92	$227.40	$171	$62.60
Tax benefit related to share-based compensation expense		29.9	66.1	45.7	17
Reduction in income		62.1	161.3	125.3	45.6
Share-based compensation cost included in inventory		1.7	1.7		1.7	1.2
Cost of goods sold (excluding amortization of acquired intangible assets)
Stock-Based Compensation
Allocated share-based compensation expense		6.1	12.6	9.2	3.3
Research and development
Stock-Based Compensation
Allocated share-based compensation expense		41.7	100.5	75.8	27.2
Selling, general and administrative
Stock-Based Compensation
Allocated share-based compensation expense		$44.20	$114.30	$86	$32.10

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 2) (USD $)	9 Months Ended			3 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
	Stock Options	Restricted Stock Units	Performance- Based Restricted Stock Units	superceded maximum	Maximum
Share-Based Compensation
Vested in period, total fair value				$4	$6
Stock option activity
Outstanding at the beginning of the Period (in shares)	42,592
Granted (in shares)	6,639
Exercised/Released (in shares)	-9,951
Forfeited (in shares)	-863
Expired (in shares)	-36
Outstanding at the end of the period (in shares)	38,381
Restricted and Performance-Based Restricted Stock Units
Nonvested at the beginning of the period, Share Equivalent		4,463	26
Granted, Share Equivalent		1,517	45
Exercised, Share Equivalent		-832	-6
Forfeited, Share Equivalent		-173	-8
Nonvested at the end of the period, Share Equivalent		4,975	57
Compensation cost and expected weighted-average period related to nonvested awards
Unrecognized compensation cost	$369.70	$243.60	$4.40
Expected weighted-average period in years of compensation cost to be recognized	2 years 2 months 12 days	1 year 7 months 6 days	1 year 9 months 18 days

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Income Tax Disclosure [Abstract]
Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities	$2.20
Increases to the amount of unrecognized tax benefits		$23.60

Collaboration_Agreements_Detai

Collaboration Agreements (Details)

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, except Share data, unless otherwise specified

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Mar. 31, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

USD ($)

USD ($)

USD ($)

USD ($)

Equity Securities and Other Assets

Morphosys

Morphosys

Morphosys

Morphosys

Acetylon

Acetylon

Bluebird

Bluebird

Bluebird

research and development payments FORMA

regulatory approval milestone FORMA

license payments FORMA

Forma

MorphoSys AG

MorphoSys AG

Other Collaboration Arrangements

All Collaboration Agreements Partners

All Collaboration Agreements Partners

USD ($)

USD ($)

EUR (€)

Collaborative Arrangement

Collaborative Arrangement

USD ($)

milestone payments maximum Acetylon

USD ($)

Celgene

USD ($)

USD ($)

USD ($)

Celgene

Morphosys

USD ($)

USD ($)

USD ($)

Maximum

Maximum

Maximum

USD ($)

EUR (€)

USD ($)

Collaboration Agreements Transactions

Potential milestone payments per product

$225

Co-development and Profit Sharing Ratio Due to Reduction of Milestones

50.00%

50.00%

50.00%

50.00%

Notice period required to be given before termination of agreement

6 months

6 months

90 days

Potential milestone payments

664.5

511

1,100

200

315

430

373

research and development period

4 years

Upfront payments made

152.1

117

Upfront share payments made

797,150

797,150

Aggregate Collaboration Agreement Payments

100

Investments in equity or other assets

12

Research and development

$584.50

$441.50

$1,495

$1,250.70

$171.30

$348.80

Commitments_and_Contingencies_

Commitments and Contingencies Commitments and Contingencies (Details) (NantHealth LLC, CSS Institute, Parent Company of NantHealth LLC, USD $)	Sep. 30, 2013
In Millions, unless otherwise specified
NantHealth LLC | CSS Institute | Parent Company of NantHealth LLC
Business Acquisition [Line Items]
Potential milestone payment	$25

Legal_Proceedings_Details

Legal Proceedings (Details)	3 Months Ended	9 Months Ended	0 Months Ended
	Sep. 30, 2012	Sep. 30, 2013	Jun. 07, 2013	Jun. 07, 2013
	US_Attorney_Office	Defendant	revlimid royalty	pomalyst royalty
Product Liability Contingency [Line Items]
Number of other U.S. Attorney offices conducting investigations	2
Royalty rate			1.00%	2.50%
Number of defendants in suit		3